var title_f29_61_30672="IVUS transducers";
var content_f29_61_30672=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intracoronary ultrasound transducer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There are two types of intracoronary ultrasound transducers: phased array or solid state (left)&nbsp;and mechanical (right). The solid state transducer has multiple fixed transducer elements at the tip of the catheter while the mechanical transducer utilizes a single transducer that rotates rapidly to visualize 360&ordm;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from Yock P, Fitzgerald P, Popp R. Science and Medicine 1995; 2:68; illustration by Nadine B Sokol.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_61_30672=[""].join("\n");
var outline_f29_61_30672=null;
var title_f29_61_30673="CPAM newborn chest x-ray";
var content_f29_61_30673=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of a type 2 congenital pulmonary airway malformation (CPAM)*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph of a newborn with a type 2 congenital pulmonary airway malformation (CPAM) in the right upper lobe. Large cysts are present inferiorly, and smaller more homogeneous cysts are present superiorly.",
"    <div class=\"footnotes\">",
"     * CPAM was previously known as congenital cystic adenomatoid malformation (CCAM).",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher M Oermann, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_61_30673=[""].join("\n");
var outline_f29_61_30673=null;
var title_f29_61_30674="Patient information: Aphasia (The Basics)";
var content_f29_61_30674=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?12/14/12512\">",
"         Patient information: Carotid artery disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/23/26994\">",
"         Patient information: Dysarthria (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/34/22050\">",
"         Patient information: Hemorrhagic stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/58/34722\">",
"         Patient information: High blood pressure in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/40/39554\">",
"         Patient information: Lowering the risk of having another stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/37/36435\">",
"         Patient information: Medicines after an ischemic stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/45/3795\">",
"         Patient information: Recovery after stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/22/35170\">",
"         Patient information: Transient ischemic attack (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/63/8180\">",
"         Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/53/19286\">",
"         Patient information: Ischemic stroke treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/37/38484\">",
"         Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Aphasia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/aphasia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H5631434\">",
"      <span class=\"h1\">",
"       What is aphasia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Aphasia is the term doctors use when a person loses the ability to use or understand language. It happens when the brain is damaged in some way, usually because of a stroke.",
"     </p>",
"     <p>",
"      There are different types of aphasia. Some types affect a person&rsquo;s ability to understand speech or to read. Other types affect a person&rsquo;s ability to form speech or to write. There are many different types of aphasia. Just a few examples are listed below.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Broca's aphasia",
"        </strong>",
"        (also called &ldquo;non-fluent aphasia&rdquo; or &ldquo;expressive aphasia&rdquo;) &ndash; People with this type of aphasia can understand a lot of what is said but they have trouble speaking.",
"       </li>",
"       <li>",
"        <strong>",
"         Wernicke's aphasia",
"        </strong>",
"        (also called &ldquo;fluent aphasia&rdquo;) &ndash; People with this type of aphasia can form speech but have trouble understanding it. They produce a lot of speech that doesn&rsquo;t make sense and sometimes use made-up words. Doctors sometimes call this &ldquo;word salad.&rdquo;",
"       </li>",
"       <li>",
"        <strong>",
"         Global aphasia",
"        </strong>",
"        &ndash; People with global aphasia cannot speak or understand written or spoken language.",
"       </li>",
"       <li>",
"        <strong>",
"         Anomic aphasia",
"        </strong>",
"        &ndash; People with this type of aphasia have trouble naming specific objects. They might still be able to speak and use verbs, but they cannot recall what different things are called.",
"       </li>",
"       <li>",
"        <strong>",
"         Alexia",
"        </strong>",
"        &ndash; People with this type of aphasia lose the ability to read. They cannot understand written words. But most people who have this problem have other problems understanding language, too. In other words, alexia does not usually happen on its own.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5631449\">",
"      <span class=\"h1\">",
"       What causes aphasia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common cause of aphasia is a stroke. But other types of brain damage can cause aphasia, too. For example, people can develop aphasia after a head injury or because of a brain tumor. There is also a disorder that gradually damages the brain over time and causes a type of aphasia called &ldquo;primary progressive aphasia.&rdquo;",
"     </p>",
"     <p>",
"      The type of aphasia a person develops depends a lot on which portion of the brain is damaged.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5631464\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have aphasia, your doctor will do tests to find out exactly what parts of language you have trouble with. He or she will test your ability to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Speak and understand speech",
"       </li>",
"       <li>",
"        Read and write",
"       </li>",
"       <li>",
"        Repeat tricky words or phrases",
"       </li>",
"       <li>",
"        Solve riddles or word problems",
"       </li>",
"       <li>",
"        Describe scenes or name objects",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You might also need imaging tests, such as MRIs or CT scans, to check what parts of your brain were affected by your stroke (or whatever is causing your aphasia).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5631479\">",
"      <span class=\"h1\">",
"       Will I regain my ability to use or understand language?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People who become unable to speak can often re-learn how to speak or at least how to communicate to some degree. The same is true of people who lose the ability to understand written or spoken language.",
"     </p>",
"     <p>",
"      If you develop aphasia, you will probably need to work with a speech and language therapist. He or she can give you exercises to do to help you recover.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5631494\">",
"      <span class=\"h1\">",
"       What are the chances of a full recovery from aphasia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The chances of making a full recovery depend on a lot of factors, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        How much of the brain was damaged and what caused the damage",
"       </li>",
"       <li>",
"        What part of the brain was damaged",
"       </li>",
"       <li>",
"        How soon the person was treated following the damage",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5631509\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/45/3795?source=see_link\">",
"       Patient information: Recovery after stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/23/26994?source=see_link\">",
"       Patient information: Dysarthria (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/40/39554?source=see_link\">",
"       Patient information: Lowering the risk of having another stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/37/36435?source=see_link\">",
"       Patient information: Medicines after an ischemic stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/34/22050?source=see_link\">",
"       Patient information: Hemorrhagic stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/22/35170?source=see_link\">",
"       Patient information: Transient ischemic attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/14/12512?source=see_link\">",
"       Patient information: Carotid artery disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=see_link\">",
"       Patient information: High blood pressure in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"       Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/53/19286?source=see_link\">",
"       Patient information: Ischemic stroke treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/63/8180?source=see_link\">",
"       Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?29/61/30674?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83333 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-FBD0C7583D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_61_30674=[""].join("\n");
var outline_f29_61_30674=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5631434\">",
"      What is aphasia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5631449\">",
"      What causes aphasia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5631464\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5631479\">",
"      Will I regain my ability to use or understand language?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5631494\">",
"      What are the chances of a full recovery from aphasia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5631509\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/14/12512?source=related_link\">",
"      Patient information: Carotid artery disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/23/26994?source=related_link\">",
"      Patient information: Dysarthria (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/34/22050?source=related_link\">",
"      Patient information: Hemorrhagic stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/63/8180?source=related_link\">",
"      Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/53/19286?source=related_link\">",
"      Patient information: Ischemic stroke treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/40/39554?source=related_link\">",
"      Patient information: Lowering the risk of having another stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/37/36435?source=related_link\">",
"      Patient information: Medicines after an ischemic stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/45/3795?source=related_link\">",
"      Patient information: Recovery after stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/22/35170?source=related_link\">",
"      Patient information: Transient ischemic attack (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_61_30675="Becaplermin: Drug information";
var content_f29_61_30675=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Becaplermin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/37/7764?source=see_link\">",
"    see \"Becaplermin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F6131564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F139209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Regranex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F139219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Growth Factor, Platelet-derived;",
"     </li>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F139211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Diabetic ulcers (lower extremity):",
"     </b>",
"     Topical: Apply appropriate amount of gel once daily with a cotton swab or similar tool, as a coating over the ulcer. The amount of becaplermin to be applied will vary depending on the size of the ulcer area.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If the ulcer does not decrease in size by ~30% after 10 weeks of treatment or complete healing has not occurred in 20 weeks, continued treatment with becaplermin gel should be reassessed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Estimation of gel requirement:",
"     </i>",
"     To calculate the length of gel applied to the ulcer, measure the greatest length of the ulcer by the greatest width of the ulcer. Tube size and unit of measure will determine the formula used in the calculation. Recalculate amount of gel needed every 1-2 weeks, depending on the rate of change in ulcer area.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Centimeters:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     15 g tube: [ulcer length (cm) x width (cm)] divided by 4 = length of gel (cm)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2 g tube: [ulcer length (cm) x width (cm)] divided by 2 = length of gel (cm)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Inches:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     15 g tube: [length (in) x width (in)] x 0.6 = length of gel (in)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2 g tube: [length (in) x width (in)] x 1.3 = length of gel (in)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F139212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F139199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Regranex&reg;: 0.01% (2 g [DSC], 15 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F139186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6131603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only. Squeeze appropriate amount of gel onto clean measuring surface (eg, wax paper), spread onto entire ulcer area in a thin, continuous layer ~",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      16",
"     </sub>",
"     inch thick. Cover with saline moistened dressing; leave dressing in place ~12 hours. After 12 hours, remove dressing, rinse with saline or water to remove residual becaplermin gel and cover with saline moistened dressing (without becaplermin gel) for remainder of the day. Continue use once daily until ulcer is completely healed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F139200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive treatment of diabetic neuropathic ulcers occurring on the lower limbs and feet that extend into subcutaneous tissue (or beyond) and have adequate blood supply",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F139225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Regranex&reg; may be confused with Granulex&reg;, Repronex&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F139218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%: Dermatologic: Erythematous rash (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Erythema with purulent discharge, ulcer infection, tunneling of ulcer, exuberant granulation tissue, local pain, skin ulceration",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F139203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to becaplermin or any component of the formulation; known neoplasm(s) at the site(s) of application",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F139190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malignancy:",
"     <b>",
"      [U.S. Boxed Warning]: An increase in mortality secondary to systemic malignancies has been observed in a retrospective study of patients treated with &ge;3 tubes of becaplermin.",
"     </b>",
"     Malignancies of varying types have been reported; all were remote from the becaplermin treatment site. Use with caution in patients with known malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only; do not use in wounds that close by primary intention. Use with caution in ulcer wounds related to arterial or venous insufficiency and when there are thermal, electrical, or radiation burns at wound site. Effects on exposed joints, tendons, ligaments and bone have not been established.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F139195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6131565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Use in pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6131567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16257699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     It is not known if becaplermin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering becaplermin to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F139204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Regranex External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.01% (15 g): $811.79",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F139197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ulcer volume (pressure ulcers); wound area; evidence of closure; drainage (diabetic ulcers); signs/symptoms of toxicity (erythema, local infections)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F139205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Regranex (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IL, IT, KP, MT, MX, NL, NO, PL, PT, RU, SE, SK, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F139189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recombinant B-isoform homodimer of human platelet-derived growth factor (rPDGF-BB) which enhances formation of new granulation tissue, induces fibroblast proliferation and differentiation to promote wound healing; also promotes angiogenesis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F139202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Complete healing: 15% of patients within 8 weeks, 25% at 10 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Minimal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Binds to PDGF beta-receptors in normal skin and granulation tissue",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/61/30675/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seeger JD, Fife D, Ziyadeh N, et al, &ldquo;A Cohort Study of the Risk of Cancer in Regranex (Becaplermin) Users and Matched Comparators,&rdquo;",
"      <i>",
"       Pharmacoepidemiol Drug Saf",
"      </i>",
"      , 2007, 16(S2):167-8:353 [abstract of the 23rd ICPE].",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8596 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5917900B73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_61_30675=[""].join("\n");
var outline_f29_61_30675=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6131564\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139209\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139219\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139211\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139212\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139199\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139186\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6131603\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139200\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139225\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139218\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139203\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139190\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298816\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218246\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139195\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6131565\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6131567\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16257699\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139204\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139197\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139205\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139189\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139202\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8596\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8596|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/37/7764?source=related_link\">",
"      Becaplermin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_61_30676="Aggressive periodontitis";
var content_f29_61_30676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 597px\">",
"   <div class=\"ttl\">",
"    Aggressive periodontitis affecting a 16-year old African-American female",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 577px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note little or no bacterial biofilm present. There is minimal inflammation of the gingival tissues. Significant alveolar bone loss is seen radiographically around first molars and both maxillary and mandibular incisors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_61_30676=[""].join("\n");
var outline_f29_61_30676=null;
var title_f29_61_30677="Normal ear anatomy PI";
var content_f29_61_30677=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F55121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F55121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Normal ear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 505px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows the normal parts of the outer, middle, and inner ear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_61_30677=[""].join("\n");
var outline_f29_61_30677=null;
var title_f29_61_30678="Deep brain stimulation for treatment of obsessive-compulsive disorder";
var content_f29_61_30678=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Deep brain stimulation for treatment of obsessive-compulsive disorder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/61/30678/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/61/30678/contributors\">",
"     Damiaan Denys, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/61/30678/contributors\">",
"     Pelle P. de Koning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/61/30678/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/61/30678/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/61/30678/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/61/30678/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/61/30678/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H18783036\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obsessive-compulsive disorder (OCD) is a disabling and potentially chronic anxiety disorder, affecting approximately 2 to 3 percent of the population, and characterized by anxiety-provoking intrusive thoughts and repetitive behaviors.",
"   </p>",
"   <p>",
"    Effective treatments for OCD include cognitive behavioral therapy (CBT) and serotonin reuptake inhibitors. Even when optimal treatment is provided, however, approximately 10 percent of patients remain severely affected with treatment-refractory OCD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/1\">",
"     1",
"    </a>",
"    ]. Deep brain stimulation (DBS), a treatment in which implanted electrodes send electrical pulses to specific locations in the brain, may be useful for a small proportion of patients with severe, incapacitating OCD that is refractory to other treatments.",
"   </p>",
"   <p>",
"    Deep brain stimulation for OCD is discussed here. The epidemiology, clinical manifestations, diagnosis, and treatment of OCD with pharmacotherapy and psychotherapy are discussed separately. OCD in pregnant and postpartum women are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36564?source=see_link\">",
"     \"Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34391?source=see_link\">",
"     \"Psychotherapy for obsessive-compulsive disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23561?source=see_link\">",
"     \"Pharmacotherapy for obsessive-compulsive disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42582?source=see_link\">",
"     \"Obsessive-compulsive disorder in pregnant and postpartum women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1406544\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep brain stimulation (DBS) is a neurosurgical treatment involving the implantation of electrodes that send electrical impulses to specific locations in the brain (",
"    <a class=\"graphic graphic_figure graphicRef83124 \" href=\"UTD.htm?40/22/41315\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/2\">",
"     2",
"    </a>",
"    ]. Widely used in the treatment of advanced movement disorders, DBS has been investigated for treatment-resistant obsessive-compulsive disorder (OCD) since the first case reported in 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/3\">",
"     3",
"    </a>",
"    ]. DBS provides an adjustable and reversible means of neuromodulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32105?source=see_link&amp;anchor=H5#H5\">",
"     \"Surgical treatment of Parkinson disease\", section on 'Deep brain stimulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1390920\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The location of deep brain stimulation (DBS) is selected according to the type of symptoms of obsessive-compulsive disorder (OCD) to be addressed. Based on published trials and case studies, it is estimated that a total of approximately 100 patients with OCD have received experimental DBS using five different brain targets [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anterior limb of the internal capsule (ALIC)",
"     </li>",
"     <li>",
"      Ventral",
"      <span class=\"nowrap\">",
"       striatum/ventral",
"      </span>",
"      capsule",
"      <span class=\"nowrap\">",
"       (VS/VC)",
"      </span>",
"     </li>",
"     <li>",
"      Nucleus accumbens (NAc)",
"     </li>",
"     <li>",
"      Subthalamic nucleus (STN)",
"     </li>",
"     <li>",
"      Inferior thalamic peduncle (ITP)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The comparative efficacy of stimulating these different areas is not known. (See",
"    <a class=\"local\" href=\"#H18783071\">",
"     'Efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18783050\">",
"    <span class=\"h1\">",
"     MECHANISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circuits connecting orbitofrontal cortex (OFC), medial prefrontal cortex (mPFC), basal ganglia and thalamus are believed to be central to the pathophysiology and treatment response of obsessive-compulsive disorder (OCD) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the mechanism of deep brain stimulation (DBS) is unknown, a widely accepted hypothesis is that OCD is associated with hyperactivity of the cortical-striatal-pallidal-thalamic-cortical (CSTC) network [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/5\">",
"     5",
"    </a>",
"    ]. It is plausible that DBS inhibits or functionally overrides this pathological network hyperactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/6\">",
"     6",
"    </a>",
"    ]. It is most likely that the therapeutic effects of DBS are caused by a combination of direct and indirect effects dependent on the specific cytoarchitecture of the stimulated brain area. Because the field intensity of the electrode decreases exponentially with distance, neurons are influenced in various ways. Although studies demonstrating the inhibitory characteristics of DBS are sparse, research combining imaging and DBS suggests that hyperactivity in the OFC correlates with the severity of OCD, and that OFC activity normalizes following DBS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18783057\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An",
"    <span class=\"nowrap\">",
"     investigational/experimental",
"    </span>",
"    treatment for obsessive-compulsive disorder (OCD), deep brain stimulation (DBS) is typically used in patients who meet each of the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of primary OCD without major comorbid pathology.",
"     </li>",
"     <li>",
"      OCD should be severe and incapacitating, with a severity score on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) of at least 28 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      OCD should be treatment-refractory. Treatment refractoriness is generally defined by multiple, unsuccessful trials of an anti-obsessive-compulsive medication (ie, a selective serotonin reuptake inhibitor [SSRI],",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"       clomipramine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      ) at adequate dosing and duration, as well as a poor response to an adequate trial of behavioral therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23561?source=see_link\">",
"       \"Pharmacotherapy for obsessive-compulsive disorder\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34391?source=see_link\">",
"       \"Psychotherapy for obsessive-compulsive disorder\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Criteria often used for treatment-refractory OCD in DBS trials include non-response to each of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Two trials with an SSRI at the maximum dosage for three to six months.",
"     </li>",
"     <li>",
"      One trial with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"       clomipramine",
"      </a>",
"      at the maximum dosage for three to six months.",
"     </li>",
"     <li>",
"      Six months of behavioral therapy that includes exposure under the supervision of a clinical psychologist trained in behavioral techniques.",
"     </li>",
"     <li>",
"      At least one trial of an atypical antipsychotic medication used for three months in conjunction with an SSRI or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"       clomipramine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an investigational experimental treatment for OCD, use of DBS should be preceded by fully informed consent, and supported by an interdisciplinary team (including neurosurgery, psychiatry, and neurology) with expertise in diagnosing and treating OCD and able to provide close patient monitoring over time. Pending further evaluation related to patient selection, procedure methods, and treatment outcomes, DBS is not recommended for OCD outside of the research setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18783092\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients under 18 years of age &mdash; Data from long-term study suggest that OCD symptoms often improve over the life of an affected individual [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intelligence quotient (IQ) under 80 &mdash; Patients with an IQ under 80 should be assessed for their capacity to provide informed consent for the procedure.",
"     </li>",
"     <li>",
"      Clinically significant",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      unstable neurologic or medical illnesses such as significant brain atrophy, increased bleeding tendency, reduced infection defense, relevant cerebrovascular disease (eg, cerebrovascular accident) or other surgical contraindications.",
"     </li>",
"     <li>",
"      Pregnancy",
"     </li>",
"     <li>",
"      Devices generating electrical artifacts, such as cardiac pacemakers and defibrillators.",
"     </li>",
"     <li>",
"      Antisocial personality disorder",
"     </li>",
"     <li>",
"      Alcohol or substance abuse during prior six months.",
"     </li>",
"     <li>",
"      Acute psychosis (benign hallucinations",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hallucinations in the past are not exclusion criterion).",
"     </li>",
"     <li>",
"      History of one or more manic or hypomanic episodes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18783115\">",
"    <span class=\"h1\">",
"     IMPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The deep brain stimulation (DBS) system consists of three components: an implanted pulse generator (IPG), the lead (with four electrodes at the tip), and the extension cables (",
"    <a class=\"graphic graphic_figure graphicRef83124 \" href=\"UTD.htm?40/22/41315\">",
"     figure 1",
"    </a>",
"    ). The electrical impulses are generated by the IPG, which includes a battery, and is surgically implanted in the chest. An extension cable runs from the IPG, under the skin of the neck and scalp, through a burr hole in the skull, and connects to an electrode surgically implanted in the brain. The precise anatomic position of implantation is calculated beforehand on the basis of magnetic resonance and computer tomography scans. The lead is placed in the brain using a stereotactic head frame attached to the patient's skull under local anesthetic.",
"   </p>",
"   <p>",
"    In bilateral DBS (most widely",
"    <span class=\"nowrap\">",
"     performed/studied",
"    </span>",
"    in OCD), a single pulse generator is placed in the chest with two extension cable outputs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2440185\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The implanted pulse generator used for DBS contains a microchip, allowing the neurostimulation to be modified. The activity of the electrode can be programmed externally with a portable appliance communicating with the pulse generator through telemetry. These adjustments are usually made by a senior psychiatrist with expertise of the phenomenology of OCD.",
"   </p>",
"   <p>",
"    Adjustments can be made to the frequency, intensity, pulse width, and location of neurostimulation. Location is adjusted by activating different electrodes on the lead. Each electrode (usually four) can be stimulated separately. Through these adjustments, the stimulation can be modified to optimize the treatment effect and to minimize side effects.",
"   </p>",
"   <p>",
"    This adjustment phase takes on average three to six months, but may last up to 12 months. When adjustment appears to result in a clinical relevant response, the stimulation is maintained continuously. Parameters are typically adjusted on the basis of an individual patient&rsquo;s response and reported side effects such as impulsivity, sleeping problems, or tension. Twelve adjustments are needed, on average, with a two week interval between them before stable settings are arrived at. Among patients who do not appear to respond after adequate adjustment, modification continues until the best outcome is achieved. In very rare cases, in the event of absolute non-response and occurrence of side effects, the device is switched off and may eventually be removed.",
"   </p>",
"   <p>",
"    Typical stimulation parameters for DBS in OCD can vary within the following ranges:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Frequency between 2 and 185 Hertz",
"     </li>",
"     <li>",
"      Current power between 0 and 10 Volts",
"     </li>",
"     <li>",
"      Pulse widths between 60 and 150 milliseconds",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18783071\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of deep brain stimulation (DBS) for obsessive-compulsive disorder (OCD) has not been established, but preliminary trials, either uncontrolled or inadequately controlled, have shown promising results.",
"   </p>",
"   <p>",
"    A 2011 review of published case reports and trials of DBS for OCD found that 34 of 63 patients showed an improvement of 35 percent or more on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/2\">",
"     2",
"    </a>",
"    ]. The mean decrease in Y-BOCS score ranged from 6.8 to 31 points over a treatment period of 3 to 36 months. Small, open trials, using randomly assigned periods of active or sham stimulation for periods ranging from two weeks to three months, reported Y-BOCS changes ranging from 2.8 to 12.5 points [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18783078\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These trials examined stimulation of five different anatomic areas in the brain; however, due to the small size of the studies and differences in their methods, no conclusions can be drawn on comparative outcomes from stimulating different brain regions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/2,12-14\">",
"     2,12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In case of non-response to adequate parameter adjustments, continuing modification can still result in some degree of decreased symptoms, which in the worst case is still an improvement of 10 percent in a sample of 16 patients with treatment refractory OCD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no known patient factors or clinician factors associated with superior outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1391539\">",
"    <span class=\"h2\">",
"     Concurrent antidepressant effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;DBS has been associated with reduction of depressive symptoms in patients with OCD and comorbid depression, a common comorbidity. Studies have reported improvement in mood after stimulation of the nucleus accumbens, anterior limb of the internal capsule, and ventral",
"    <span class=\"nowrap\">",
"     striatum/ventral",
"    </span>",
"    capsule [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Antidepressive effects seem to be related to DBS of the ventral striatum in particular; no mood improvement was observed following stimulation of the subthalamic nucleus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36564?source=see_link&amp;anchor=H2#H2\">",
"     \"Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis\", section on 'Epidemiology and spectrum of disease'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1390920\">",
"     'Anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Preliminary studies have been conducted on DBS for treatment-resistant depression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of resistant depression in adults\", section on 'Deep brain stimulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18783078\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep brain stimulation (DBS) is associated with different types of adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complications related to surgical implantation of the device",
"     </li>",
"     <li>",
"      Device or hardware-related problems",
"     </li>",
"     <li>",
"      Undesired effects caused by stimulation or cessation of stimulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1391415\">",
"    <span class=\"h2\">",
"     Surgical complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;As an invasive procedure, DBS implantation can be associated with surgical complications. However, serious adverse effects have been infrequent in OCD and in DBS treatment of movement disorders, which have been more extensively studied and involve devices and implantation procedures similar to those for OCD. A review of 360 patients who underwent DBS implementation for movement disorders experienced a mortality rate of 0.6 percent and a rate of adverse effects with permanent neurological sequelae of 2.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/17\">",
"     17",
"    </a>",
"    ]. Surgical complications that did not lead to permanent effects included infection, hemorrhage, confusion, and seizures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32105?source=see_link&amp;anchor=H12#H12\">",
"     \"Surgical treatment of Parkinson disease\", section on 'Surgical complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1391422\">",
"    <span class=\"h2\">",
"     Hardware complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hardware problems after DBS implantation, including device malfunction, lead migration, and infection, are not uncommon, with aggregate reported rates of approximately 11 to 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32105?source=see_link&amp;anchor=H13#H13\">",
"     \"Surgical treatment of Parkinson disease\", section on 'Hardware complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1391351\">",
"    <span class=\"h2\">",
"     Stimulation related complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stimulation-related complications vary widely by type and may be specific to the area of the brain that is stimulated. (See",
"    <a class=\"local\" href=\"#H1390920\">",
"     'Anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    These adverse effects are usually reversible by adjustment of stimulation parameters or cessation of stimulation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transient hypomania is the most commonly seen side effect of DBS for OCD [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/14\">",
"       14",
"      </a>",
"      ]. Hypomania seems to occur frequently (in 50 to 67 percent of cases) in association with stimulation in the ventral",
"      <span class=\"nowrap\">",
"       striatum/ventral",
"      </span>",
"      capsule&ndash;nucleus accumbens region, but has also been seen with DBS administered to other brain areas, including the globus pallidus, subthalamic nucleus (4 to 8 percent of cases), and the anterior limb of the internal capsule&ndash;nucleus accumbens regions [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cessation of deep brain stimulation in OCD can result in severe worsening of mood and anxiety. This can be reversed by reactivation of the stimulation.",
"     </li>",
"     <li>",
"      Apart from transient diminished concentration and verbal perseverations [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/14\">",
"       14",
"      </a>",
"      ], DBS has not been associated with evident decline or improvement in cognitive functioning. However, the literature on the subject is sparse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Optimizing the parameter settings of the neurostimulator can reduce stimulation side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18783085\">",
"    <span class=\"h1\">",
"     CONCURRENT TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with obsessive-compulsive disorder (OCD) often continue to take antidepressant and antipsychotic medications while receiving deep brain stimulation (DBS).",
"   </p>",
"   <p>",
"    There are no trials that have specifically studied the efficacy of medication or psychotherapy in combination with DBS treatment for OCD. In one small trial, however, investigators noted that cognitive behavioral therapy administered concurrently with DBS appeared to be particularly effective in decreasing compulsive behavior and avoidance, and that gains appeared to be lost after stimulation was discontinued.",
"   </p>",
"   <p>",
"    In the absence of data to guide practice, remaining depressive, OCD or anxiety symptoms during DBS could reasonably be treated with a serotonergic antidepressant, benzodiazepine, or CBT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1391070\">",
"    <span class=\"h1\">",
"     ALTERNATIVE INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative, experimental interventions for severe, treatment-refractory OCD include ablative neurosurgical techniques and transcranial magnetic stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/4,18\">",
"     4,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1391040\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deep brain stimulation (DBS) is a neurosurgical treatment involving the implantation of electrodes that send electrical impulses to specific locations in the brain (",
"      <a class=\"graphic graphic_figure graphicRef83124 \" href=\"UTD.htm?40/22/41315\">",
"       figure 1",
"      </a>",
"      ). An effective treatment for selected patients with advanced Parkinson disease, DBS is an investigational treatment for incapacitating, treatment-refractory OCD. (See",
"      <a class=\"local\" href=\"#H1406544\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32105?source=see_link\">",
"       \"Surgical treatment of Parkinson disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although the mechanism of deep brain stimulation (DBS) is unknown, a widely accepted hypothesis is that OCD is associated with hyperactivity of the cortical-striatal-pallidal-thalamic-cortical (CSTC) network [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30678/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18783050\">",
"       'Mechanism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The frequency, intensity, pulse width and location of the neurostimulation can be adjusted over the course of treatment; this may increase effectiveness and reduce side effects of DBS treatment. (See",
"      <a class=\"local\" href=\"#H2440185\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The efficacy of DBS for OCD has not been established, but preliminary trials, either uncontrolled or inadequately controlled, have shown promising results. Of 63 patients with treatment refractory OCD who have received DBS, 34 experienced a reduction of symptoms of 35 percent or more. (See",
"      <a class=\"local\" href=\"#H18783071\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DBS implantation is an invasive procedure that can cause infection, hemorrhage, confusion, or seizures. Severe adverse effects are uncommon; the mortality rate has been estimated at 0.6 percent. Hardware malfunctions, which can generally be corrected, are more common. Stimulation-related complications are usually reversible by adjusting the stimulation. Large randomized trials are needed to determine the treatment&rsquo;s efficacy and safety. (See",
"      <a class=\"local\" href=\"#H18783078\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DBS is an experimental procedure that has been used to treat incapacitating and treatment-refractory OCD. Given the invasive nature of DBS and the lack of efficacy data, we suggest that patients with OCD only be treated with DBS in the context of a clinical trial (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18783071\">",
"       'Efficacy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18783078\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30678/abstract/1\">",
"      Denys D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr Clin North Am 2006; 29:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30678/abstract/2\">",
"      de Koning PP, Figee M, van den Munckhof P, et al. Current status of deep brain stimulation for obsessive-compulsive disorder: a clinical review of different targets. Curr Psychiatry Rep 2011; 13:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30678/abstract/3\">",
"      Nuttin B, Cosyns P, Demeulemeester H, et al. Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder. Lancet 1999; 354:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30678/abstract/4\">",
"      Greenberg BD, Rauch SL, Haber SN. Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD. Neuropsychopharmacology 2010; 35:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30678/abstract/5\">",
"      Meissner W, Leblois A, Hansel D, et al. Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations. Brain 2005; 128:2372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30678/abstract/6\">",
"      McIntyre CC, Hahn PJ. Network perspectives on the mechanisms of deep brain stimulation. Neurobiol Dis 2010; 38:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30678/abstract/7\">",
"      Le Jeune F, V&eacute;rin M, N'Diaye K, et al. Decrease of prefrontal metabolism after subthalamic stimulation in obsessive-compulsive disorder: a positron emission tomography study. Biol Psychiatry 2010; 68:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30678/abstract/8\">",
"      Abelson JL, Curtis GC, Sagher O, et al. Deep brain stimulation for refractory obsessive-compulsive disorder. Biol Psychiatry 2005; 57:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30678/abstract/9\">",
"      Miller MH, Wexler MA, Steigbigel NH. Single and combination antibiotic therapy of Staphylococcus aureus experimental endocarditis: emergence of gentamicin-resistant mutants. Antimicrob Agents Chemother 1978; 14:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30678/abstract/10\">",
"      Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30678/abstract/11\">",
"      Skoog G, Skoog I. A 40-year follow-up of patients with obsessive-compulsive disorder [see commetns]. Arch Gen Psychiatry 1999; 56:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30678/abstract/12\">",
"      Mallet L, Polosan M, Jaafari N, et al. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med 2008; 359:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30678/abstract/13\">",
"      Denys D, Mantione M, Figee M, et al. Deep brain stimulation of the nucleus accumbens for treatment-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2010; 67:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30678/abstract/14\">",
"      Greenberg BD, Gabriels LA, Malone DA Jr, et al. Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry 2010; 15:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30678/abstract/15\">",
"      Martin JL, Barbanoj MJ, Schlaepfer TE, et al. Transcranial magnetic stimulation for treating depression. Cochrane Database Syst Rev 2002; :CD003493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30678/abstract/16\">",
"      Fitzgerald PB, Brown TL, Marston NA, et al. Transcranial magnetic stimulation in the treatment of depression: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 2003; 60:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30678/abstract/17\">",
"      Pahwa R, Factor SA, Lyons KE, et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30678/abstract/18\">",
"      Blom RM, Figee M, Vulink N, Denys D. Update on repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: different targets. Curr Psychiatry Rep 2011; 13:289.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16174 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-DF5911362B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_61_30678=[""].join("\n");
var outline_f29_61_30678=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1391040\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18783036\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1406544\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1390920\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18783050\">",
"      MECHANISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18783057\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18783092\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18783115\">",
"      IMPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2440185\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18783071\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1391539\">",
"      Concurrent antidepressant effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18783078\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1391415\">",
"      Surgical complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1391422\">",
"      Hardware complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1391351\">",
"      Stimulation related complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18783085\">",
"      CONCURRENT TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1391070\">",
"      ALTERNATIVE INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1391040\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/16174\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/16174|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/22/41315\" title=\"figure 1\">",
"      Deep brain stimulation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42582?source=related_link\">",
"      Obsessive-compulsive disorder in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36564?source=related_link\">",
"      Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23561?source=related_link\">",
"      Pharmacotherapy for obsessive-compulsive disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34391?source=related_link\">",
"      Psychotherapy for obsessive-compulsive disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32105?source=related_link\">",
"      Surgical treatment of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_61_30679="Beta blockers in the management of stable angina pectoris";
var content_f29_61_30679=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Beta blockers in the management of stable angina pectoris",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/61/30679/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/61/30679/contributors\">",
"     Joseph P Kannam, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/61/30679/contributors\">",
"     Julian M Aroesty, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/61/30679/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/61/30679/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/61/30679/contributors\">",
"     Freek Verheugt, MD, FACC, FESC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/61/30679/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/61/30679/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/61/30679/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers are first-line therapy in the control of symptoms in patients with chronic stable angina, particularly effort-induced angina. They are recommended for use in such patients in guidelines from the American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    College of",
"    <span class=\"nowrap\">",
"     Physicians/American",
"    </span>",
"    Association for Thoracic",
"    <span class=\"nowrap\">",
"     Surgery/Preventive",
"    </span>",
"    Cardiovascular Nurses",
"    <span class=\"nowrap\">",
"     Association/Society",
"    </span>",
"    for Cardiovascular Angiography and",
"    <span class=\"nowrap\">",
"     Interventions/Society",
"    </span>",
"    of Thoracic Surgeons",
"    <span class=\"nowrap\">",
"     (ACCF/AHA/ACP/AATS/PCNA/SCAI/STS)",
"    </span>",
"    and from the European Society of Cardiology [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major issues regarding the use of beta blockers in the medical management of the patient with stable angina and the evidence that these drugs are effective will be reviewed here. Their role, compared with other drugs, in the overall management of angina is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiologic effects of catecholamines (norepinephrine and epinephrine) are mediated by activation of specific alpha and beta adrenergic receptors. There are at least three distinct types of beta receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta-1, which are found primarily in heart muscle. Activation of these receptors results in increases in heart rate, contractility, and atrioventricular (AV) conduction, and a decrease in AV node refractoriness.",
"     </li>",
"     <li>",
"      Beta-2, which are present in heart muscle but are more prominent in bronchial and peripheral vascular smooth muscle. Activation of these receptors results in vasodilatation and bronchodilatation.",
"     </li>",
"     <li>",
"      Beta-3, which are found in adipose tissue and the heart. Activation of these receptors may mediate catecholamine-induced thermogenesis and may reduce cardiac contractility [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Beta blockers act by competitively inhibiting catecholamines from binding to these receptors. Some are more selective for the beta-1 receptor. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Cardioselectivity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Upregulation of beta receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta receptor density is a dynamic process that can change under varying physiologic conditions. In particular, chronic beta blocker therapy leads to an increase in receptor density [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/7\">",
"     7",
"    </a>",
"    ]. This can be clinically important, since sudden withdrawal of the beta blocker results in transient supersensitivity to catecholamines, possibly precipitating angina, myocardial infarction, or death [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. These complications can occur even in patients without previously apparent coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=see_link&amp;anchor=H5#H5\">",
"     \"Major side effects of beta blockers\", section on 'Beta blocker withdrawal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cardiovascular effects of beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The beneficial therapeutic effects of beta blockade in patients with stable angina pectoris are mediated by a reduction in myocardial oxygen demand. Myocardial oxygen demand varies directly with heart rate, contractility, and left ventricular wall stress, each of which is diminished by beta blockade. The decrease in wall stress is mediated in part by the antihypertensive action of these drugs.",
"   </p>",
"   <p>",
"    The decline in heart rate is determined both by the degree to which the heart rate is sympathetically activated (as with exercise or stress) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/10\">",
"     10",
"    </a>",
"    ] and to the properties of the beta blocker. Those drugs with intrinsic sympathomimetic activity may actually increase the resting heart rate. They are, however, still effective in the treatment of angina because it is the reduction in the exercise heart rate that is of primary importance. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Intrinsic sympathomimetic activity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The negative inotropic effects of beta blockers may, at least theoretically, have a favorable impact on myocardial oxygen consumption in the patient with angina. In the past, beta blockers were avoided in patients with left ventricular dysfunction, from concern that negative inotropic effects could precipitate or worsen heart failure. However, extensive clinical experience and the results of major clinical trials have demonstrated that these agents actually prolong survival in patients with heart failure. In such patients, beta blocker therapy should be initiated at low dose, and volume overload should be corrected prior to the initiation of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Beta blockers may also affect coronary blood flow, although there are competing effects. Beta blockers inhibit adrenergically mediated coronary vasodilation, thereby increasing coronary vascular resistance and decreasing coronary blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/11\">",
"     11",
"    </a>",
"    ]. However, this potentially deleterious effect is overcome by the reductions in heart rate (which enhances coronary perfusion by prolonging diastole) and myocardial oxygen demand.",
"   </p>",
"   <p>",
"    Nonselective beta blockers may exacerbate coronary vasospasm in patients with variant angina and should be avoided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=see_link\">",
"     \"Variant angina\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of different beta blockers are available for clinical use. Properties such as pharmacokinetics, cardioselectivity, intrinsic sympathomimetic activity, and alpha adrenergic blocking activity are important characteristics that should be considered when choosing a particular agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the beta blockers have similar pharmacotherapeutic effects, their pharmacokinetic properties differ significantly in ways that may influence their clinical usefulness and side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/12\">",
"     12",
"    </a>",
"    ]. Among individual drugs, there are differences in completeness of gastrointestinal absorption, amount of first-pass hepatic metabolism, lipid solubility, protein binding, extent of distribution in the body, penetration into the brain, concentration in the heart, rate of hepatic biotransformation, pharmacologic activity of metabolites, and renal clearance of the drug and its metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the basis of their pharmacokinetic properties, the beta blockers can be classified into two broad categories [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Those eliminated by hepatic metabolism",
"     </li>",
"     <li>",
"      Those excreted unchanged by the kidney",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Drugs in the first group (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ) are lipid-soluble, almost completely absorbed by the small intestine, and largely metabolized by the liver. They enter the central nervous system (CNS) in high concentrations, possibly resulting in an increased incidence of CNS side effects. They tend to have highly variable bioavailability and relatively short plasma half-lives.",
"   </p>",
"   <p>",
"    In contrast, drugs in the second category (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ) are more water soluble, incompletely absorbed through the gut, eliminated unchanged by the kidney, and do not as readily enter the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. They show less variance in bioavailability and have longer plasma half-lives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cardioselectivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardioselectivity refers to the ability of a drug to preferentially block the beta-1 receptors. Nonselective beta blockers have equal affinity for the beta-1 and beta-2 receptors, while cardioselective agents will primarily inhibit the beta 1-receptors. Cardioselectivity is a relative property and substantial beta-2 receptor blockade can also occur at the higher doses that are often required to treat angina [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Intrinsic sympathomimetic activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some beta blockers (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10487?source=see_link\">",
"     pindolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37047?source=see_link\">",
"     acebutolol",
"    </a>",
"    ) have intrinsic sympathomimetic activity (ISA), also called partial agonist activity, providing low-grade beta stimulation at rest but acting as typical beta blockers when sympathetic activity is high [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Alpha-adrenergic blocking activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     Labetalol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    block both beta and alpha receptors. As a result, they reduce peripheral and coronary vascular resistance. They are both non-selective beta blockers without ISA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS OF BETA BLOCKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers are generally well tolerated in patients with stable angina, but have a well recognized set of potential side effects that can limit their use. The major side effects of beta blockers are discussed fully elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=see_link\">",
"     \"Major side effects of beta blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most frequent adverse effects include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreases in heart rate, contractility, and AV node conduction.",
"     </li>",
"     <li>",
"      Bronchoconstriction, due to beta-2 receptor blockade, can be induced by nonselective agents and high doses of cardioselective agents. As a result, many clinicians have assumed that chronic obstructive pulmonary disease (COPD) or asthma is a contraindication to beta blocker therapy. However, beta blockers are safe and effective in patients with mild",
"      <span class=\"nowrap\">",
"       COPD/asthma",
"      </span>",
"      who are not taking a beta-2 adrenergic agonist. Furthermore, some patients carry a diagnosis of COPD that has not been confirmed. The data supporting these observations primarily come from studies of patients with an acute coronary syndrome and are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link&amp;anchor=H7#H7\">",
"       \"Beta blockers in the management of acute coronary syndrome\", section on 'COPD/asthma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Worsening of symptoms of peripheral artery disease or Raynaud phenomenon. However, there appears to be no adverse effect on mild to moderate claudication symptoms when beta-1 selective blockers are used. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link&amp;anchor=H5#H5\">",
"       \"Medical management of claudication\", section on 'Hypertension'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=see_link\">",
"       \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fatigue may be due to the reduction in cardiac output or to direct effects on the central nervous system.",
"     </li>",
"     <li>",
"      Central side effects that can occur include nightmares, insomnia, and hallucinations. Although depression is often mentioned as a side effect of beta blockers, this association was not seen in randomized trials. Central side effects may be more common in older adults.",
"     </li>",
"     <li>",
"      Erectile dysfunction is often a problem [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EFFICACY OF BETA BLOCKERS IN STABLE ANGINA",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the beta blockers, regardless of pharmacologic properties, appear to be equally effective in the treatment of stable angina pectoris. They improve exercise capacity, reduce exercise-induced ST depression, decrease the frequency of anginal episodes, and diminish the requirement for sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    . No randomized trials have examined the effect of beta blockers on survival in patients with stable angina. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Survival'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Nonselective agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     Propranolol",
"    </a>",
"    was the first beta blocker introduced clinically. It is a nonselective agent that has been used extensively for stable angina.",
"   </p>",
"   <p>",
"    Evidence of long-term efficacy was provided in a study of 63 patients with severe stable angina who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    for five to eight years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/18\">",
"     18",
"    </a>",
"    ]. A 50 percent or greater reduction in anginal episodes occurred in 84 percent of patients. Those with a lesser or no response had a four-fold increase in mortality. There was no evidence of tachyphylaxis to beta blockade.",
"   </p>",
"   <p>",
"    Drug dose is an important determinant of response in patients with angina. Daily doses of 160 and 320 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , but not 80 mg, appear to be required [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cardioselective drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, cardioselective beta blockers (the most commonly used being",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ) offer the potential advantage of not interfering with bronchodilatation or peripheral vasodilatation. The clinical applicability of this effect is uncertain since cardioselectivity may be lost at the high doses needed to treat angina [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/15\">",
"     15",
"    </a>",
"    ]. Nevertheless, cardioselective drugs are used in most patients with stable angina.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     Atenolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    are as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    (and more effective than placebo) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    in reducing anginal attacks and increasing exercise capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. In addition, once daily dosing of atenolol is as effective (and more convenient) as twice daily dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/21\">",
"     21",
"    </a>",
"    ]. Metoprolol is available in a short acting form (metoprolol tartrate) for twice daily dosing and in a long acting form (metoprolol succinate) for once daily dosing.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    was demonstrated in the International Multicenter Angina Exercise (IMAGE) study in which 280 patients with chronic stable angina were randomly assigned to six weeks therapy with long-acting preparations of metoprolol (200 mg daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    (20 mg twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/23\">",
"     23",
"    </a>",
"    ]. Metoprolol reduced the frequency of angina and increased the mean exercise time to 1-mm ST segment depression. Furthermore, the increase in exercise time was significantly greater than that seen with nifedipine (70 versus 43 seconds).",
"   </p>",
"   <p>",
"    Use of an appropriate dose is important. One report compared 25, 50, 100, and 200 mg once daily dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    with placebo in patients with angina [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/24\">",
"     24",
"    </a>",
"    ]. All doses were more effective than placebo in reducing angina and the need for sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    ; however, only the 100 and 200 mg doses increased exercise capacity (",
"    <a class=\"graphic graphic_figure graphicRef56323 \" href=\"UTD.htm?9/58/10159\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Agents with intrinsic sympathomimetic activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10487?source=see_link\">",
"     Pindolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37047?source=see_link\">",
"     acebutolol",
"    </a>",
"    are as effective in treating angina as other beta blockers but have the potential advantage of causing less depression of cardiac function. One report, for example, compared the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    and pindolol in 52 patients with stable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/25\">",
"     25",
"    </a>",
"    ]. Both agents were equally effective in relieving angina, but pindolol caused less pronounced resting bradycardia or impairment in left ventricular function. In another study, pindolol (when compared to propranolol) was associated with a higher resting heart rate and, at low levels of exercise, a higher heart rate, cardiac output, oxygen consumption was higher in the pindolol group [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/16\">",
"     16",
"    </a>",
"    ]. These differences disappeared at higher rates of exercise.",
"   </p>",
"   <p>",
"    Despite some potential benefits, these drugs are rarely used in the treatment of stable angina except possibly in patients with underlying resting bradycardia. They may not decrease heart rate and blood pressure at rest and should not be given to patients with a prior myocardial infarction or heart failure in whom beta blockade improves survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Agents with alpha blocking activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     Carvedilol",
"    </a>",
"    is a nonselective beta blocker that has vasodilating properties as a result of selective alpha-1 antagonism. One study of 122 patients with chronic stable angina found that carvedilol, at doses of 25 or 50 mg twice daily, was superior to placebo, significantly increasing the time to angina and to one mm ST segment depression during exercise testing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/26\">",
"     26",
"    </a>",
"    ]. There was no difference in the frequency of side effects when compared to placebo. In another randomized trial, carvedilol was at least as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data are more limited with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    but demonstrate significant reductions in heart rate and angina frequency and an increase in exercise time [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to control of angina symptoms, beta blockers improve survival in certain subgroups of patients with stable coronary disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have had a myocardial infarction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link\">",
"       \"Beta blockers in the management of acute coronary syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with systolic heart failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"       \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, beta blockers have never been shown to improve survival or reduce the incidence of myocardial infarction in patients with chronic stable angina in the absence of myocardial infarction or heart failure. This issue is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link&amp;anchor=H37#H37\">",
"     \"Secondary prevention of cardiovascular disease\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     THERAPEUTIC GOALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary therapeutic goal of beta blockers in chronic stable angina is to reduce the frequency and severity of angina and to improve exercise capacity without significant side effects. As noted above, the efficacy of beta blockers in relieving angina is dose-dependent. It is therefore important to be certain that adequate beta blockade has been attained.",
"   </p>",
"   <p>",
"    Reasonable goals when titrating the dose include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resting heart rate between 50 and 60",
"      <span class=\"nowrap\">",
"       beats/min.",
"      </span>",
"      The 2002",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines on stable angina recommend adjusting the beta blocker dose to achieve a resting heart rate of 55 to 60",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      and this was not changed in the 2007 focused update [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. Among patients with more severe angina, the goal may be less than 50",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      assuming the absence of symptoms due to bradycardia or heart block. In addition, the exercise heart rate should not exceed 75 percent of the heart rate associated with the onset of ischemia.",
"      <br/>",
"      <br/>",
"      Patients with resting bradycardia prior to therapy can be treated with a calcium channel blocker (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      ), nitrates, or, if a beta blocker is necessary, a drug with intrinsic sympathomimetic activity. Similar considerations apply to patients with atrioventricular conduction delay.",
"     </li>",
"     <li>",
"      Blunting of peak heart rate and blood pressure during exercise which can be measured by the patient or during exercise testing, if performed.",
"     </li>",
"     <li>",
"      Reduction in the frequency and severity of angina as well as the use of sublingual",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Absence of significant side effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CHOOSING AN AGENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the general efficacy of most beta blockers in the management of stable angina, ancillary properties, such as dosing interval and cost, become important considerations when determining which beta blocker to use. We generally use a cardioselective agent (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ). There are no major advantages of a nonselective agent, other than the low cost of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , and there are potential disadvantages in patients with certain underlying diseases such as obstructive lung disease, asthma, peripheral artery disease, diabetes, and depression.",
"   </p>",
"   <p>",
"    Beta blockers with intrinsic sympathomimetic activity are rarely used in the treatment of stable angina except possibly in patients with underlying resting bradycardia. They may not decrease heart rate and blood pressure at rest and should not be given to patients with a prior myocardial infarction or heart failure in whom beta blockade improves survival.",
"   </p>",
"   <p>",
"    We agree with the 2012",
"    <span class=\"nowrap\">",
"     (ACCF/AHA/ACP/AATS/PCNA/SCAI/STS)",
"    </span>",
"    guideline on the diagnosis and management of stable ischemic heart disease, which reached the following conclusions on the role of beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30679/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta blockers are recommended as initial therapy for the relief of anginal symptoms in patients with stable ischemic heart disease. Calcium channel blockers and long-acting nitrates are recommended when beta blockers are contraindicated or poorly tolerated and in addition to beta blockers when angina persists with beta blocker monotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H381820810\">",
"    <span class=\"h2\">",
"     Patients with heart failure due to systolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of beta blockers in patients with heart failure due to systolic dysfunction is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers are highly effective in the reduction of symptoms of angina and the development of myocardial ischemia in stable patients. However, they have never been shown to decrease mortality in these individuals in the absence of myocardial infarction or heart failure associated with a reduction in left ventricular systolic function.",
"   </p>",
"   <p>",
"    There are many different beta blockers approved for use for cardiovascular disorders. Since it is difficult to remember the ancillary properties, pharmacokinetics, and doses of all these agents, the physician should become familiar with one or two agents in each class (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10487?source=see_link\">",
"     pindolol",
"    </a>",
"    ) for cardioselective, nonselective, and ISA, respectively. The choice of agent depends upon the clinical setting since all beta blockers are equally effective in treating angina.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unless contraindicated, we recommend that all patients with stable angina pectoris receive a beta blocker as first-line antianginal therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest using a cardioselective agent, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/1\">",
"      Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/2\">",
"      Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:e354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/3\">",
"      Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:3097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/4\">",
"      Lands AM, Arnold A, McAuliff JP, et al. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967; 214:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/5\">",
"      Gauthier C, Tavernier G, Charpentier F, et al. Functional beta3-adrenoceptor in the human heart. J Clin Invest 1996; 98:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/6\">",
"      Krief S, L&ouml;nnqvist F, Raimbault S, et al. Tissue distribution of beta 3-adrenergic receptor mRNA in man. J Clin Invest 1993; 91:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/7\">",
"      Lefkowitz RJ, Caron MG, Stiles GL. Mechanisms of membrane-receptor regulation. Biochemical, physiological, and clinical insights derived from studies of the adrenergic receptors. N Engl J Med 1984; 310:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/8\">",
"      Frishman WH. Beta-adrenergic blocker withdrawal. Am J Cardiol 1987; 59:26F.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/9\">",
"      Psaty BM, Koepsell TD, Wagner EH, et al. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA 1990; 263:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/10\">",
"      LeWinter MM, Crawford MH, Karliner JS, ORourke RA. Effects of oral propranolol in normal subjects. Clin Pharmacol Ther 1975; 17:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/11\">",
"      Nayler WG, Carson V. Effect of stellate ganglion stimulation on myocardial blood flow, oxygen consumption, and cardiac efficiency during beta-adrenoceptor blockade. Cardiovasc Res 1973; 7:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/12\">",
"      Opie LH. Drugs and the heart. Lancet 1980; 1:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/13\">",
"      Frishman W. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic properties. Am Heart J 1979; 97:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/14\">",
"      Frishman WH, Lazar EJ, Gorodokin G. Pharmacokinetic optimisation of therapy with beta-adrenergic blocking agents. Clin Pharmacokinet 1991; 20:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/15\">",
"      Lertora JJ, Mark AL, Johannsen J, et al. Selective beta-1 receptor blockade with oral practolol in man. A dose-related phenomenon. J Clin Invest 1975; 56:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/16\">",
"      Magder S, Sami M, Ripley R, Lisbona R. Comparison of the effects of pindolol and propranolol on exercise performance in patients with angina pectoris. Am J Cardiol 1987; 59:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/17\">",
"      Wassertheil-Smoller S, Oberman A, Blaufox MD, et al. The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life. Am J Hypertens 1992; 5:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/18\">",
"      Warren SG, Brewer DL, Orgain ES. Long-term propranolol therapy for angina pectoris. Am J Cardiol 1976; 37:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/19\">",
"      Alderman EL, Davies RO, Crowley JJ, et al. Dose response effectiveness of propranolol for the treatment of angina pectoris. Circulation 1975; 51:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/20\">",
"      Furberg B, Dahlqvist A, Raak A, Wrege U. Comparison of the new beta-adrenoceptor antagonist, nadolol, and propranolol in the treatment of angina pectoris. Curr Med Res Opin 1978; 5:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/21\">",
"      Jackson G, Harry JD, Robinson C, et al. Comparison of atenolol with propranolol in the treatment of angina pectoris with special reference to once daily administration of atenolol. Br Heart J 1978; 40:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/22\">",
"      Borer JS, Comerford MB, Sowton E. Assessment of metoprolol, a cardioselective beta-blocking agent, during chronic therapy in patients with angina pectoris. J Int Med Res 1976; 4:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/23\">",
"      Savonitto S, Ardissiono D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1996; 27:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/24\">",
"      Jackson G, Schwartz J, Kates RE, et al. Atenolol: once-daily cardioselective beta blockade for angina pectoris. Circulation 1980; 61:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/25\">",
"      Kostis JB, Frishman W, Hosler MH, et al. Treatment of angina pectoris with pindolol: the significance of intrinsic sympathomimetic activity of beta blockers. Am Heart J 1982; 104:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/26\">",
"      Weiss R, Ferry D, Pickering E, et al. Effectiveness of three different doses of carvedilol for exertional angina. Carvedilol-Angina Study Group. Am J Cardiol 1998; 82:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/27\">",
"      Hauf-Zachariou U, Blackwood RA, Gunawardena KA, et al. Carvedilol versus verapamil in chronic stable angina: a multicentre trial. Eur J Clin Pharmacol 1997; 52:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/28\">",
"      Quyyumi AA, Wright C, Mockus L, et al. Effects of combined alpha and beta adrenoceptor blockade in patients with angina pectoris. A double blind study comparing labetalol with placebo. Br Heart J 1985; 53:47.",
"     </a>",
"    </li>",
"    <li>",
"     Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30679/abstract/30\">",
"      Fraker TD Jr, Fihn SD, 2002 Chronic Stable Angina Writing Committee, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 2007; 50:2264.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1466 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-79.122.249.114-3C057D9C1B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_61_30679=[""].join("\n");
var outline_f29_61_30679=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Upregulation of beta receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cardiovascular effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHARMACOLOGIC CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cardioselectivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Intrinsic sympathomimetic activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Alpha-adrenergic blocking activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADVERSE EFFECTS OF BETA BLOCKERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EFFICACY OF BETA BLOCKERS IN STABLE ANGINA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Nonselective agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cardioselective drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Agents with intrinsic sympathomimetic activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Agents with alpha blocking activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      THERAPEUTIC GOALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CHOOSING AN AGENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H381820810\">",
"      Patients with heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1466\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1466|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/58/10159\" title=\"figure 1\">",
"      Atenolol dose in angina",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=related_link\">",
"      Medical management of claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=related_link\">",
"      Variant angina",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_61_30680="Didanosine: Pediatric drug information";
var content_f29_61_30680=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Didanosine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"    see \"Didanosine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/13/38101?source=see_link\">",
"    see \"Didanosine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F159665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Videx&reg;;",
"     </li>",
"     <li>",
"      Videx&reg; EC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F159666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Videx&reg;;",
"     </li>",
"     <li>",
"      Videx&reg; EC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HIV Agents (Anti-HIV Agents)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nucleoside Reverse Transcriptase Inhibitor (NRTI)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment of HIV infection:",
"     </b>",
"     Use in combination with other antiretroviral agents: Oral solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     PNA &lt;14 days: Dose not established; pharmacokinetic parameters are too variable to determine appropriate dosage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     PNA &ge;14 days: Oral solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer's labeling: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     AIDS",
"     <i>",
"      info",
"     </i>",
"     recommendation (DHHS [pediatric], 2012): 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 12 hours;",
"     <b>",
"      Note:",
"     </b>",
"     Based on pharmacokinetic data, Panel members suggest toxicity may occur using manufacturer dosing in this age group.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment",
"     </b>",
"     : Insufficient data exists to recommend a specific dosage adjustment; however, a decrease in the dose should be considered in pediatric patients with renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"      see \"Didanosine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"     <b>",
"      Treatment of HIV infection:",
"     </b>",
"     Oral: Use in combination with other antiretroviral agents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants 1-8 months: Oral solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer's labeling: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AIDS",
"     <i>",
"      info",
"     </i>",
"     recommendation (DHHS [pediatric], 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants 1 to &lt;3 months: 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 12 hours;",
"     <b>",
"      Note:",
"     </b>",
"     Based on pharmacokinetic data, panel members suggest toxicity may occur using manufacturer dosing in the age group.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants &gt;3-8 months: Oral solution: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &gt;8 months and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Manufacturer's labeling: 120 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 12 hours; do not exceed adult dose; once-daily dosing of the oral solution is not FDA approved in children; limited data is available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     AIDS",
"     <i>",
"      info",
"     </i>",
"     recommendation (DHHS [pediatric], 2012): 120 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 12 hours; Maximum dose: 200 mg;",
"     <b>",
"      Note:",
"     </b>",
"     Pediatric clinical studies used doses of 90-150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Delayed release capsule: Children &ge;6 years and &ge;20 kg who are able to swallow a capsule whole:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     20 kg to &lt;25 kg: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     25 kg to &lt;60 kg: 250 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;60 kg: 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral solution:",
"     <b>",
"      Note:",
"     </b>",
"     Although once-daily dosing is available, it should only be considered for adolescent/adult patients whose management requires once-daily administration (eg, to enhance compliance); the preferred dosing frequency of didanosine oral solution is twice daily because there is more evidence to support the effectiveness of this dosing frequency:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;60 kg: 125 mg every 12 hours",
"     <b>",
"      or",
"     </b>",
"     250 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;60 kg: 200 mg every 12 hours or 400 mg once daily using a special  Videx&reg; solution in double strength antacid which provides 400 mg/20 mL for once-daily dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Delayed release capsule:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     20 kg to &lt;25 kg: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     25 kg to &lt;60 kg: 250 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;60 kg: 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Treatment of HIV infection:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dosing based on patient weight:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Pediatric powder for oral solution (Videx&reg;):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;60 kg: 125 mg twice daily (preferred) or 250 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;60 kg: 200 mg twice daily (preferred) or 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Delayed release capsule (Videx&reg; EC):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     25 kg to &lt;60 kg: 250 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;60 kg: 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     When taken with tenofovir:",
"     <b>",
"      Note:",
"     </b>",
"     Combined use of tenofovir with didanosine is no longer recommended (DHHS [adult], 2013; [pediatric], 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;60 kg and Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;60 kg and Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: 250 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute: Dose has not been established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children: Insufficient data exists to recommend a specific dosage adjustment; however, a decrease in the dose should be considered in pediatric patients with renal impairment. The following guidelines have been used by some clinicians (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-29 mL/minute: 90 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemodialysis:  75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 24 hours after dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peritoneal dialysis:  75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents and Adults: Dosing based on patient weight, creatinine clearance, and dosage form:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Dosing for patients &lt;60 kg:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge; 60 mL/minute: No dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-59 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Oral solution: 75 mg twice daily or 150 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Delayed release capsule: 125 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-29 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Oral solution: 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Delayed release capsule: 125 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Oral solution: 75 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Delayed release capsule: Use alternate formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Dosing for patients &ge;60 kg:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: No dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-59 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Oral solution: 100 mg twice daily or 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Delayed release capsule: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-29 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Oral solution: 150 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Delayed release capsule: 125 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Oral solution: 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Delayed release capsule: 125 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in patients requiring continuous ambulatory peritoneal dialysis (CAPD) or hemodialysis:",
"     </b>",
"     Adults: Use dosing recommendations for patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute; supplemental doses following hemodialysis are not needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     No adjustment recommended; Adults: In a single-dose study, mean AUC and peak serum concentrations of didanosine were 13% and 19% higher, respectively, in adults with moderate to severe hepatic impairment (Child-Pugh Class B or C). However, a similar range and distribution of AUC and peak concentrations were observed. It is important to monitor patients with hepatic impairment closely for didanosine toxicity. Patients with hepatic impairment may be at increased risk for didanosine toxicities.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F159637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, delayed release, enteric coated beadlets, oral: 125 mg, 200 mg, 250 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Videx&reg; EC: 125 mg, 200 mg, 250 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, delayed release, enteric coated pellets, oral: 200 mg, 250 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral [pediatric]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Videx&reg;: 2 g/bottle, 4 g/bottle",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F159622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Delayed release capsule",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9845084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Videx&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM199211.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM199211.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Videx&reg; EC:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM199212.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM199212.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer oral solution and delayed release capsule on an empty stomach 30 minutes before or at least 2 hours after a meal. Swallow capsule whole; do not break open or chew. If administered with tenofovir, the delayed release capsule may be administered with a light meal or in the fasted state. Administer didanosine at least 1 hour apart from indinavir. Administer didanosine at least 2 hours apart from ritonavir or atazanavir. Didanosine should be given at least 1 hour before or 2 hours after lopinavir/ritonavir. Nelfinavir should be administered 2 hours before or 1 hour after didanosine. Administer buffered formulations of didanosine at least 1 hour apart from fosamprenavir.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Unbuffered pediatric powder should be reconstituted with water and admixed in equal parts with a double-strength antacid to provide a final concentration of 10 mg/mL; unbuffered pediatric powder has also been reconstituted and admixed with a double-strength antacid to provide a final concentration of 20 mg/mL to be used for once-daily dosing in adults; shake oral solution well before use.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1052235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Undergoes rapid degradation when exposed to an acidic environment; 10% of the drug decomposes to hypoxanthine in &lt;2 minutes at pH &lt;3 at 37&deg;C.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delayed release capsules: Store in tightly closed bottles at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for oral solution: Unreconstituted powder should be stored at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Powder for oral solution is unbuffered and must be reconstituted with water and mixed with an equal volume of double-strength antacid at time of preparation. Reconstituted solution (10 mg/mL) is stable for 30 days if refrigerated; discard unused portion after 30 days. When unbuffered powder for oral solution is reconstituted and admixed with a double-strength antacid to make a 20 mg/mL solution for adult once-daily dosing, the admixture is stable for 24 hours at room temperature and for 30 days if refrigerated",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infection in combination with other antiretroviral agents (Oral solution: FDA approved in ages &ge;2 weeks and adults; Delayed release capsule: FDA approved in ages &ge;6 years and adults);",
"     <b>",
"      Note:",
"     </b>",
"     HIV regimens consisting of",
"     <b>",
"      three",
"     </b>",
"     antiretroviral agents are strongly recommended",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F159715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Videx&reg; may be confused with Lidex&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F159713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As reported in monotherapy studies; risk of toxicity may increase when combined with other agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Uric acid increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, amylase increased, diarrhea, pancreatitis (patients &gt;65 years of age had a higher frequency of pancreatitis than younger patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute renal impairment, alopecia, anaphylactoid reaction, anemia, anorexia, arthralgia, chills/fever, diabetes mellitus, dry eyes, dyspepsia, flatulence, granulocytopenia, hepatic steatosis, hepatitis, hyper-/hypoglycemia, hyperlactatemia (symptomatic), hypersensitivity,  immune reconstitution syndrome, lactic acidosis/hepatomegaly, leukopenia, lipodystrophy, liver failure, myalgia, myopathy, optic neuritis, pain, parotid gland enlargement, portal hypertension (noncirrhotic), retinal depigmentation, rhabdomyolysis, sialoadenitis, Stevens-Johnson syndrome, thrombocytopenia, weakness, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to didanosine or any component; concurrent therapy with allopurinol or ribavirin",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal or hepatic impairment. Adjust dosage in patients with renal impairment. Monitor patients with hepatic impairment closely; these patients may be at risk for didanosine-associated liver function abnormalities, including severe and potentially fatal hepatic adverse events. Avoid using the combination of didanosine, stavudine, and hydroxyurea; fatal hepatic events were reported most often in HIV patients receiving this combination. Due to an increased risk of serious toxicities, the combined use of stavudine and didanosine is",
"     <b>",
"      not",
"     </b>",
"     recommended, unless the potential benefit clearly outweighs the risks (DHHS [adult], 2013; [pediatric], 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fat redistribution and accumulation [ie, central obesity, peripheral wasting, facial wasting, breast enlargement, dorsocervical fat enlargement (buffalo hump), and cushingoid appearance] have been observed in patients receiving antiretroviral agents (causal relationship not established).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Immune  reconstitution syndrome (an acute inflammatory response to residual or indolent opportunistic infections) may occur in HIV patients during initial treatment with combination antiretroviral agents, including didanosine; this syndrome may require further patient assessment and therapy. Autoimmune disorders (eg, Grave&rsquo;s disease, Guillain-Barr&eacute; syndrome, and polymyositis) have been reported in patients experiencing immune reconstitution; time to onset is variable and may occur many months after antiretroviral treatment is initiated.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1052230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fatal and nonfatal pancreatitis have been reported during therapy",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; more common in adults than children [1% to 7% vs 3% (normal doses)]; other risk factors for developing pancreatitis include a previous history of the condition, higher doses (eg, &gt;10 mg/kg/day), renal impairment without dose adjustment, concurrent CMV or MAC infection, advanced HIV infection, and concomitant use of stavudine with or without hydroxyurea; use didanosine with extreme caution and only if clearly indicated in patients with risk factors for pancreatitis; discontinue didanosine if clinical signs of pancreatitis occur; only after pancreatitis has been ruled out should dosing be resumed. Dose-related (treatment-limiting) peripheral neuropathy occurs most often after 2-6 months of continuous didanosine administration; may occur more frequently in patients with a history of neuropathy, advanced HIV disease, or concurrent treatment with neurotoxic drugs, including stavudine or hydroxyurea; consider discontinuation of didanosine in patients who develop peripheral neuropathy. Retinal depigmentation in children receiving doses &gt;300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day may occur; retinal changes and optic neuritis have been reported in pediatric and adult patients; perform periodic retinal examinations.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Cases of lactic acidosis, severe hepatomegaly with steatosis, and death have been reported in patients receiving nucleoside analogs",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most of these cases have been in women; prolonged nucleoside use, obesity, and prior liver disease may be risk factors; use with extreme caution in patients with other risk factors for liver disease; discontinue therapy in patients who develop laboratory or clinical evidence of lactic acidosis or pronounced hepatotoxicity. Fatal lactic acidosis has occurred in pregnant women who received didanosine plus stavudine with other antiretroviral agents; use didanosine plus stavudine with caution during pregnancy and only if benefit outweighs risks.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Didanosine-associated noncirrhotic portal hypertension may occur; cases leading to liver transplantation or death have been reported. Onset of signs and symptoms of portal hypertension occurred within months to years of initiating didanosine. Patients may present with increased liver enzymes, hematemesis, esophageal varices, splenomegaly, and ascites. Monitor patients for early signs of portal hypertension (eg, splenomegaly, thrombocytopenia); consider appropriate laboratory testing; discontinue didanosine in patients with evidence of noncirrhotic portal hypertension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F159631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Didanosine. Specifically, the risk of pancreatitis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May increase the serum concentration of Didanosine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Didanosine may decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May decrease the serum concentration of Didanosine. Reported with enteric coated didanosine capsules. Didanosine may decrease the serum concentration of Atazanavir. Specifically, the buffered formulation of didanosine may decrease atazanavir absorption. Management: To avoid therapeutic failure of atazanavir the drug should be administered 2 hours before or 1 hour after didanosine.  This recommendation applies to both buffered didanosine products and enteric coated didanosine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May decrease the serum concentration of Didanosine. More specifically, this interaction is likely due to the effects of food (with which darunavir/ritonavir are taken) on didanosine, which is supposed to be given on an empty stomach. Management: Didanosine should be administered 1 hour prior to or 2 hours after administration of darunavir/ritonavir (which must be taken with food).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Febuxostat: May increase the serum concentration of Didanosine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydroxyurea: May enhance the adverse/toxic effect of Didanosine. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist. Didanosine may enhance the adverse/toxic effect of Hydroxyurea. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Didanosine may decrease the serum concentration of Indinavir.  Management: Indinavir should be administered on an empty stomach at least 1 hour apart from administration of buffer-containing formulations of didanosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May decrease the serum concentration of Didanosine. This interaction refers only to lopinavir/ritonavir oral solution, which must be taken with food, and is principally the result of a food-didanosine interaction. Management: Didanosine should be administered 1 hour prior to or 2 hours after administration of lopinavir/ritonavir oral solution (which must be taken with food).  Didanosine and lopinavir/ritonavir tablets can be administered together.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: May decrease the serum concentration of Didanosine. Management: If use of methadone with didanosine is necessary, enteric coated didanosine is preferred.  Avoid using didanosine powder for solution with methadone.  Increased monitoring of clinical response to didanosine (including viral load) is necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Didanosine may decrease the serum concentration of Quinolone Antibiotics. Quinolone Antibiotics may decrease the serum concentration of Didanosine.  Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May enhance the adverse/toxic effect of Didanosine. Ribavirin may increase serum concentrations of the active metabolite(s) of Didanosine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Didanosine may decrease the absorption of Rilpivirine. More specifically, simultaneous coadministration of these drugs creates a conflict between recommendations to administer with (rilpivirine) and without (didanosine) food. Rilpivirine may decrease the absorption of Didanosine. More specifically, simultaneous coadministration of these drugs creates a conflict between recommendations to administer with (rilpivirine) and without (didanosine) food.  Management: Administer didanosine on an empty stomach at least 2 hours before or 4 hours after rilpivirine, due to the requirement that rilpivirine be administered with food.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stavudine: May enhance the adverse/toxic effect of Didanosine. Lactic acidosis (possibly fatal) is of particular concern. Management: Use extreme caution and monitor for lactic acidosis with concomitant stavudine and didanosine therapy. Avoid use of stavudine and didanosine (in combination or alone) with hydroxyurea due to increased risk of serious toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: May diminish the therapeutic effect of Didanosine. Tenofovir may increase the serum concentration of Didanosine. Management: Avoid concomitant treatment with tenofovir and didanosine.  Consider altering even existing, stable treatment to avoid this combination.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May decrease the serum concentration of Didanosine. Management: It is recommended that didanosine be administered at least 2 hours apart from tipranavir in order to minimize any potential dosage form-related interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1052249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food significantly decreases bioavailability (Oral solution: ~55%, EC capsule: ~19%). Do not mix with fruit juice or other acid-containing liquid since didanosine is unstable in acidic solutions",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F159633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F159648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Didanosine has been shown to cross the placenta. Based on data from the Antiretroviral Pregnancy Registry, an increased rate of birth defects has been observed following maternal use of didanosine during pregnancy; no pattern of defects has been observed and clinical relevance is uncertain. Pharmacokinetics are not significantly altered during pregnancy; dose adjustments are not needed. Cases of lactic acidosis/hepatic steatosis syndrome related to mitochondrial toxicity have been reported in pregnant women with prolonged use of nucleoside analogues. It is not known if pregnancy itself potentiates this known side effect; however, women may be at increased risk of lactic acidosis and liver damage. In addition, these adverse events are similar to other rare but life-threatening syndromes which occur during pregnancy (eg, HELLP syndrome). Hepatic enzymes and electrolytes should be monitored in women receiving nucleoside analogues and clinicians should watch for early signs of the syndrome. In addition, mitochondrial dysfunction may develop in infants following",
"     <i>",
"      in utero",
"     </i>",
"     exposure. Due to the reports of lactic acidosis, maternal, and neonatal mortality, didanosine and stavudine should",
"     <b>",
"      not",
"     </b>",
"     be used in combination during pregnancy. The DHHS Perinatal HIV Guidelines recommend didanosine to be used only in special circumstances during pregnancy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum antiretroviral (ARV) drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV), also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Monitor CD4 percentage (if &lt;5 years of age) or CD4 count (if &ge;5 years of age) at least every 3-4 months (DHHS [pediatric], 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Prior to initiation of therapy: Genotypic resistance testing, CD4, viral load, CBC with differential, LFTs, BUN, creatinine. At initiation and with any change in treatment regimen: CBC with differential, electrolytes, calcium, phosphate, glucose, LFTs, bilirubin, BUN, creatinine, albumin, total protein, lipid panel, CD4, and viral load. After 4-8 weeks of therapy: CBC with differential, viral load; then every 3-4 months: CBC with differential, electrolytes, glucose, LFTs, bilirubin, BUN, creatinine, CD4, and viral load. Albumin, total protein, calcium, phosphate, lipid panel, and urinalysis every 6-12 months (DHHS [pediatric], 2012). Monitor for signs of opportunistic infections, pancreatitis, or lactic acidosis",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     To monitor for portal hypertension: CBC with platelet count, splenomegaly on physical exam, liver enzymes, serum bilirubin, albumin, INR, ultrasound",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A purine dideoxynucleoside analog converted within the cell to an active metabolite, dideoxyadenosine triphosphate which serves as a substrate and inhibitor of viral RNA-directed DNA polymerase resulting in premature termination of viral DNA synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Subject to degradation by acidic pH of stomach; some formulations are buffered to resist acidic pH. Delayed release capsules contain enteric-coated beadlets which dissolve in the small intestine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Extensive intracellular distribution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CSF/plasma ratio:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 8 months to Adolescents 19 years: 46% (range: 12% to 85%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 21%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     (apparent):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Age-based:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants 8 months to Adolescents 19 years: 28 &plusmn; 15 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adults: 43.7 &plusmn; 8.9 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weight-based:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 20 kg to &lt;25 kg: 98 &plusmn; 30 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 25 kg to &lt;60 kg: 155 &plusmn; 55 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;60 kg: 363 &plusmn; 138 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adults &ge;60 kg: 308 &plusmn; 164 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &lt;5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Converted intracellularly to active triphosphate form; presumed to be metabolized via the same metabolic pathway as endogenous purines",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Variable and affected by the presence of food in the GI tract, gastric pH, and the dosage form administered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants 8 months to Adolescents 19 years: 25% &plusmn; 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 42% &plusmn; 12%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plasma:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Newborns (1 day old): 2 &plusmn; 0.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 2 weeks to 4 months: 1.2 &plusmn; 0.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 8 months to Adolescents 19 years: 0.8 &plusmn; 0.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults with normal renal function: 1.5 &plusmn; 0.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intracellular: Adults: 25-40 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 20 kg to &lt;25 kg: 0.75 &plusmn; 0.13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 25 kg to &lt;60 kg: 0.92 &plusmn; 0.09 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;60 kg: 1.26 &plusmn; 0.19 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults &ge;60 kg: 1.19 &plusmn; 21 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Delayed release capsules: 2 hours; Oral solution: 0.25-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Unchanged drug excreted in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants 8 months to Adolescents 19 years: 18% &plusmn; 10%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 18% &plusmn; 8%",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1052237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/13/38101?source=see_link\">",
"      see \"Didanosine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The patient Medication Guide is dispensed with each prescription and refill of didanosine. Avoid alcohol. Shake oral solution well before use and keep refrigerated; discard solution after 30 days and obtain new supply. The buffered powder vehicle may contribute to the development of diarrhea.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Inform physician if numbness, tingling, or pain in hands or feet; persistent severe abdominal pain, nausea, or vomiting; or changes in vision occur. Didanosine may cause serious and potentially fatal problems of the pancreas and liver. Serious eye problems have also been reported.  Frequent blood tests and periodic eye examinations may be required. HIV medications may cause changes in body fat, including an increase in fat in the upper back and neck, breasts, and trunk; a loss of fat from the face, arms, and legs may also occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Didanosine is not a cure for HIV. Take didanosine every day as prescribed; do not change dose or discontinue without physician's advice. If a dose is missed, take it as soon as possible, then return to normal dosing schedule; if a dose is skipped, do",
"     <b>",
"      not",
"     </b>",
"     double the next dose.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1052247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Once daily, didanosine delayed-release capsules have been approved for use in children 6-18 years of age who are &ge;20 kg. This approval was based on pharmacokinetic studies; however, limited published literature exists. In a single-dose pharmacokinetic study in children 4-11.5 years of age (n=10; median age: 7.6 years), a dose of 240 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     was shown to have a similar plasma AUC as compared to the buffered formulation. However, two patients were excluded from data analysis, one due to extremely low didanosine serum concentrations throughout the dosing interval (King, 2002). Doses of 240 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily, with a maximum of 400 mg once daily, are being studied in pediatric clinical trials.",
"     <b>",
"      Note:",
"     </b>",
"     In PACTG 1021, treatment-na&iuml;ve children (3-21 years of age) received 240 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily (maximum: 400 mg/dose) with good viral suppression (DHHS [pediatric], 2012). Children with a surface area &ge;0.45 m",
"     <sup>",
"      2",
"     </sup>",
"     who could swallow capsules received the delayed-release capsule; the oral suspension was used for smaller children (McKinney, 2007).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The relative bioavailability of didanosine suspension administered once daily versus twice daily was studied in 24 children, 4.8 &plusmn; 2.9 years of age. Didanosine was administered in doses of 90 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 12 hours and 180 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily. The relative bioavailability of once-daily dosing compared to twice daily dosing was 0.95 &plusmn; 0.49 (range: 0.22-1.97). The authors suggest these results support the potential clinical use of once-daily dosing in pediatric patients. However, due to the large inter- and intrasubject variability, these 2 regimens would",
"     <b>",
"      not",
"     </b>",
"     be considered to be bioequivalent based on FDA criteria (Abreu, 2000). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     A high rate of early virologic failure in therapy-naive adult HIV patients has been observed with the once-daily three-drug combination therapy of didanosine enteric-coated beadlets (Videx&reg; EC), lamivudine, and tenofovir and the once-daily three-drug combination therapy of abacavir, lamivudine, and tenofovir. These combinations should not be used or offered at any time. Any patient currently receiving either of these regimens should be closely monitored for virologic failure and considered for treatment modification. Early virologic failure was also observed in therapy-naive adult HIV patients treated with tenofovir, didanosine enteric-coated beadlets (Videx&reg; EC), and either efavirenz or nevirapine; rapid emergence of resistant mutations has also been reported with this combination; the combination of tenofovir, didanosine, and any non-nucleoside reverse transcriptase inhibitor is",
"     <b>",
"      not",
"     </b>",
"     recommended as initial antiretroviral therapy.",
"     <b>",
"      Note:",
"     </b>",
"     Didanosine plus tenofovir is",
"     <b>",
"      not",
"     </b>",
"     recommended as a component to any initial antiretroviral therapy regimen.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     One major study found an increased risk of MI in patients receiving didanosine; however, other cohort studies did not find an increased cardiovascular risk (DHHS [adult], 2013).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aberg JA, Kaplan JE, Libman H, et al, \"Primary Care Guidelines for the Management of Persons Infected With Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 49(5):651-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/61/30680/abstract-text/19640227/pubmed\" id=\"19640227\" target=\"_blank\">",
"        19640227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Abreu T, Plaisance K, Rexroad V, et al, \"Bioavailability of Once- and Twice-Daily Regimens of Didanosine in Human Immunodeficiency Virus-Infected Children,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2000, 44(5):1375-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/61/30680/abstract-text/10770783/pubmed\" id=\"10770783\" target=\"_blank\">",
"        10770783",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Balis FM, Pizzo PA, Butler KM, et al, &ldquo;Clinical Pharmacology of 2&prime;, 3&prime;-Dideoxyinosine in Human Immunodeficiency Virus-Infected Children,&rdquo;",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 1992, 165(1):99-104.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/61/30680/abstract-text/1727902/pubmed\" id=\"1727902\" target=\"_blank\">",
"        1727902",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Butler KM, Husson RN, Balis FM, et al, &ldquo;Dideoxyinosine in Children With Symptomatic Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 324(3):137-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/61/30680/abstract-text/1670591/pubmed\" id=\"1670591\" target=\"_blank\">",
"        1670591",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, \"Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,\" February 12, 2013. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, \"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,\" November 5, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      King JR, Nachman S, Yogev R, et al, \"Single-Dose Pharmacokinetics of Enteric-Coated Didanosine in HIV-Infected Children,\"",
"      <i>",
"       Antivir Ther",
"      </i>",
"      , 2002, 7(4):267-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/61/30680/abstract-text/12553481/pubmed\" id=\"12553481\" target=\"_blank\">",
"        12553481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kovari H, Ledergerber B, Peter U, et al, \"Association of Noncirrhotic Portal Hypertension in HIV-Infected Persons and Antiretroviral Therapy With Didanosine: A Nested Case-Control Study,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 49(4):626-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/61/30680/abstract-text/19589079/pubmed\" id=\"19589079\" target=\"_blank\">",
"        19589079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McKinney RE Jr, Rodman J, Hu C, et al, \"Long-Term Safety and Efficacy of a Once-Daily Regimen of Emtricitabine, Didanosine, and Efavirenz in HIV-Infected, Therapy-Naive Children and Adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 120(2):e416-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/61/30680/abstract-text/17646352/pubmed\" id=\"17646352\" target=\"_blank\">",
"        17646352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12691 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-219.243.220.100-C5CC09C3EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_61_30680=[""].join("\n");
var outline_f29_61_30680=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708701\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159665\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159666\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052239\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442298\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052232\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159637\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159622\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9845084\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052243\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052235\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052242\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159715\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159713\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052246\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052231\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052230\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299187\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159631\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052249\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159633\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159648\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052238\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052229\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052245\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052237\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052247\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12691\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12691|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=related_link\">",
"      Didanosine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/13/38101?source=related_link\">",
"      Didanosine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_61_30681="Vulvovaginal varicosities and pelvic congestion syndrome";
var content_f29_61_30681=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vulvovaginal varicosities and pelvic congestion syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/61/30681/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/61/30681/contributors\">",
"     Natasha R Johnson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/61/30681/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/61/30681/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/61/30681/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/61/30681/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/61/30681/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/61/30681/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/61/30681/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/61/30681/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pelvic venous syndromes, which include pelvic congestion syndrome and vulvar varicosities, are poorly understood disorders of the pelvic venous circulations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pelvic congestion syndrome (PCS) is characterized by chronic pelvic discomfort exacerbated by prolonged standing and coitus in women who have periovarian varicosities on imaging studies. The etiology of PCS is unclear and the optimum treatment is uncertain. Development of an evidence-based approach to managing these patients has been limited by the absence of definitive diagnostic criteria.",
"     </li>",
"     <li>",
"      Vulvar varicosities result from venous obstruction, increased venous pressure, and venous insufficiency, most commonly during pregnancy. They may be isolated or associated with varices of the lower extremity, and they may occur as part of PCS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VULVOVAGINAL VARICOSITIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that 4 percent of women have had vulvar varicosities [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/1\">",
"     1",
"    </a>",
"    ]. They usually occur during pregnancy and typically regress spontaneously within six weeks postpartum. They are rare in nulliparous women. When they occur in non-pregnant women, they generally present in the second or third decade of life [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathogenesis/pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar varicosities are dilated venous channels that probably develop from a combination of proximal venous obstruction and valvular incompetence, which results in increased venous pressure. Their anatomy has been defined by direct injection and surgical dissection of the varices.",
"   </p>",
"   <p>",
"    The vascular drainage of the female external genitalia includes the dorsal superficial clitoral, bulbovestibular, profundus clitoral, and posterior labial veins. Because these perineal veins do not have valves, they are susceptible to the development of varices. Up to one-half of vulvar varicosities arise from an incompetent great saphenous vein, which drains the superficial and deep external pudendal veins and posteromedial tributaries.",
"   </p>",
"   <p>",
"    Insufficiency of the internal iliac and ovarian veins may also contribute to development of varicose veins over the territories of their main tributaries (ie, the internal pudendal and obturator veins). Such varices can be large, have frequent anastomoses, and involve the vulva and posteromedial aspect of the thigh [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Rarely, vulvar varices arise from the round ligament vein, mimicking varicocele in the male [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/1,7\">",
"     1,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vulvar varicosities are most common in pregnant women because anatomic and physiologic changes associated with pregnancy result in pelvic venous congestion. Proposed mechanisms include (1) increased pelvic blood flow, which impairs venous return via the femoral veins and thus contributes to venous congestion in the lower limbs and pelvis, and (2) mechanical compression of the inferior vena",
"    <span class=\"nowrap\">",
"     cava/iliac",
"    </span>",
"    veins by the gravid uterus, which increases venous pressure distally [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/6,8-10\">",
"     6,8-10",
"    </a>",
"    ]. In addition, hormonal changes likely contribute by causing vasodilation.",
"   </p>",
"   <p>",
"    Vulvar varices in nulliparous women are also caused by local venous insufficiency and incompetence; genetic factors likely play a role in predisposition to these venous changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with vulvar varices are often asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/1\">",
"     1",
"    </a>",
"    ]. Symptomatic women may describe vulvar discomfort, swelling, and pressure that are exacerbated by prolonged standing, exercise, and coitus. In nonpregnant women, symptoms may be aggravated by menses and may represent a manifestation of PCS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/1,3,11-14\">",
"     1,3,11-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of vulvar varicosities is based on physical examination (",
"    <a class=\"graphic graphic_picture graphicRef86312 \" href=\"UTD.htm?24/28/25039\">",
"     picture 1",
"    </a>",
"    ). Patients should be examined in both the supine and upright positions, since the latter enhances filling of the veins. The varicosities appear as purple-blue distensible folds in the vaginal mucosa and labia or as a grape-like cluster of veins (\"bag of worms\") in the enlarged vulva (",
"    <a class=\"graphic graphic_figure graphicRef76766 \" href=\"UTD.htm?37/10/38048\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/8,9,15\">",
"     8,9,15",
"    </a>",
"    ]. They may be isolated or associated with varices of the buttocks, thigh, or lower leg.",
"   </p>",
"   <p>",
"    There is no consensus on indications for imaging. Imaging is not necessary to confirm the diagnosis, which is evident on physical examination, but may be useful in therapeutic planning. For example, if surgery is planned for treatment of the varicosities, most vascular surgeons would obtain duplex ultrasound studies of the lower extremity veins (even in the absence of lower leg varicosities) to determine whether connections to the saphenous system are present, as these connections would alter the treatment approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/43/33462?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnostic evaluation of chronic venous insufficiency\", section on 'Duplex ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some clinicians perform magnetic resonance (MR) imaging or computed tomography (CT) to evaluate pelvic and gonadal veins in all patients with vulvar varicosities, and, if imaging is positive, they perform venography if an intervention such as coil embolization is planned.",
"   </p>",
"   <p>",
"    Others perform pelvic venography in all patients prior to any invasive therapy since vulvar varicosities caused by incompetence of ovarian veins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    internal iliac veins may recur after local therapy, thus this information may change the primary or secondary treatment approach [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/1,3,4,6,16-18\">",
"     1,3,4,6,16-18",
"    </a>",
"    ]. As an example, in a series of 25 women with vulvar varices (with and without PCS) who underwent transjugular venography, 15 women (60 percent) had left ovarian vein reflux and thus underwent coil embolization rather than local therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/4\">",
"     4",
"    </a>",
"    ]. All had complete resolution of symptoms without any procedure related complications (access infection, coil migration or venous perforation).",
"   </p>",
"   <p>",
"    If vulvar varicosities are associated with chronic pelvic pain, pelvic imaging (eg, MR, CT, venography) should be performed as part of the diagnostic evaluation for PCS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/1,3-7\">",
"     1,3-7",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H17\">",
"     'Diagnosis and diagnostic evaluation PCS'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differential diagnosis of vulvar varices includes the following [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Venous malformations, which are rare, congenital, dysmorphic vessels in the vulva. They typically present as bluish, easily compressible, nonpulsatile masses that increase in size with maneuvers that increase venous pressure. Unlike vulvar varicosities, venous malformations are often symptomatic (particularly during menses or pregnancy) and slowly grow over the patient's lifetime; they do not regress [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/8,15,19\">",
"       8,15,19",
"      </a>",
"      ]. In addition, they can be complicated by spontaneous intralesional thrombosis.",
"      <br/>",
"      <br/>",
"      Doppler ultrasound, magnetic resonance imaging, and direct injection venography have been used to distinguish between varicosities and venous malformations, but an imaging study is only required to confirm the diagnosis if invasive treatment is planned.",
"     </li>",
"     <li>",
"      Hematoma, which should be suspected in the setting of recent trauma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44071?source=see_link\">",
"       \"Evaluation and management of lower genital tract trauma in women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16455?source=see_link\">",
"       \"Management of hematomas incurred as a result of obstetrical delivery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hernia, which is characterized by absence of",
"      <span class=\"nowrap\">",
"       blue/purple",
"      </span>",
"      coloration and by increased bulging when the patient bears down or coughs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31321?source=see_link\">",
"       \"Classification, clinical features and diagnosis of inguinal and femoral hernias in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Soft-tissue neoplasm (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20618?source=see_link\">",
"       \"Differential diagnosis of vulvar lesions\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hemangiomas [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/19-23\">",
"       19-23",
"      </a>",
"      ] usually present within the first few months of life and can grow rapidly. They appear as superficial red papules or nodules, or as deep raised skin-colored nodules, which often have a",
"      <span class=\"nowrap\">",
"       bluish/black",
"      </span>",
"      hue. Hemangiomas that persist into adulthood may cause symptoms due to periodic thrombosis. Visual inspection and history can differentiate between varicosities and hemangiomas. Imaging is indicated in selected cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=see_link\">",
"       \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Arteriovenous malformation &mdash; These lesions increase in size over time due to arterial inflow and almost always require some type of ablative therapy.",
"     </li>",
"     <li>",
"      Bartholin gland cyst, which appears as a soft, painless mass in the area of the Bartholin gland (ie, medial labia majora or lower vestibular area). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22375?source=see_link\">",
"       \"Disorders of Bartholin gland\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasional complications include deep and superficial thrombophlebitis, ulceration, and hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/8,10\">",
"     8,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment depends on whether vulvar varicosities are present in isolation or associated with leg varicosities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PCS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;During pregnancy, noninvasive therapy is preferred because regression commonly occurs postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/10,24\">",
"     10,24",
"    </a>",
"    ]. There are no data to support specific therapies or one therapy over another. Supportive therapies that have been suggested include vulvar support and compression (pelvic supporter), leg elevation, compression with support hose, sleeping on the left side, exercise, and avoidance of long periods of standing or sitting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vulvar varicosities are not a contraindication to vaginal delivery. Theoretically, a laceration of large vulvovaginal varicosities could result in significant hemorrhage, but no such hemorrhages have been reported in the literature. This may be because obstetricians advise patients with massive varicosities to undergo cesarean delivery or because the varicosities collapse after delivery and their low blood flow allows bleeding to be readily controlled.",
"   </p>",
"   <p>",
"    Rarely, thrombosis of vulvar varicosities occurs during pregnancy. Conservative treatment with oral analgesics is usually effective but, local excision of the thrombus may be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/29/21977?source=see_link\">",
"     \"Open surgical techniques for lower extremity vein ablation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Sclerotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of symptomatic varices that persist for more than three months postpartum or arise in the nonpregnant state is based on size and symptoms. As with lower extremity varicosities, vulvar varices can be treated with sclerotherapy, ligation and excision, or embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/3,4,9,16,18,25,26\">",
"     3,4,9,16,18,25,26",
"    </a>",
"    ]. These techniques are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13514?source=see_link\">",
"     \"Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/29/21977?source=see_link\">",
"     \"Open surgical techniques for lower extremity vein ablation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30408?source=see_link&amp;anchor=H6#H6\">",
"     \"Interventional radiology in management of gynecological disorders\", section on 'Pelvic congestion syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to treatment of vulvar varicosities is derived from case reports and small series; no randomized trials have been performed. Based on expert opinion, sclerotherapy is the preferred treatment for isolated vulvar varicosities with no evidence of great or small saphenous vein obstruction or reflux on lower extremity duplex ultrasonography. More commonly, there is evidence of saphenous venous insufficiency with duplex ultrasound and evidence of direct communication from the saphenofemoral junction to the vulvar varicosities. In these cases, the leg veins are generally treated first and the treatment response of the vulvar varices is assessed. Local sclerotherapy can be utilized as adjunctive therapy for vulvar varices, if necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/43/33462?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnostic evaluation of chronic venous insufficiency\", section on 'Duplex ultrasonography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=see_link\">",
"     \"Overview and management of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Procedure",
"      </strong>",
"      &mdash; A solution of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1603?source=see_link\">",
"       sodium tetradecyl",
"      </a>",
"      sulfate (or other sclerosant, eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/6/110?source=see_link\">",
"       polidocanol",
"      </a>",
"      ) is injected directly into the varices; the concentration of the solution depends on the size of the veins. The patient wears a compression girdle for 48 hours after each treatment session and usually at least two to three treatment sessions are required. Patients are typically uncomfortable for three to four days, but pain can be managed adequately with oral analgesics.",
"      <br/>",
"      <br/>",
"      The injected varicosities become firm and fibrotic after sclerotherapy, with improvement in pain, pressure, and swelling within seven days of treatment. Case series have described marked improvement (100 percent response) at 6- to 12-month follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/3,9\">",
"       3,9",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Thromboses within the varices can occur if they are not compressed adequately after injection. The treatment is microthrombectomy. Other potential complications include allergy to the medication and ulceration or hyperpigmentation of the skin over the varicosities, but these complications have not been reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Ligation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical treatment for vulvar varices by ligation of incompetent veins and perforators requires multiple incisions, but can provide symptomatic relief. However, dyspareunia and cosmetic disfiguration secondary to perineal scarring are potential future complications [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Isolated vulvar varicosities can be treated with so-called \"stab\" or \"ambulatory phlebectomy,\" which utilizes very small 1 to 2 mm skin incisions through which sequential venous segments are avulsed. Surgical ligation is not performed because the incisions are too small; instead, hemostasis is achieved by compression with a bandage or stocking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laser or radiofrequency ablation is rarely possible, as varicosities of the vulva generally do not meet criteria for these treatment modalities because of the size and location of the veins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17031?source=see_link\">",
"     \"Laser and light therapy of lower extremity telangiectasias, reticular veins and small varicose veins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30809?source=see_link\">",
"     \"Radiofrequency ablation for the treatment of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PELVIC CONGESTION SYNDROME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Epidemiology PCS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to establish the true incidence of PCS, given the lack of definitive diagnostic criteria. It primarily affects multiparous women in the reproductive age group [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/1,12,13\">",
"     1,12,13",
"    </a>",
"    ]. No cases have been reported in menopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/1,12,27\">",
"     1,12,27",
"    </a>",
"    ]. The prevalence of PCS is up to 30 percent in patients presenting with chronic pelvic pain in whom no other obvious pathology can be found [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/11,28,29\">",
"     11,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pathogenesis/pathology PCS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of PCS is unclear. Multiple investigators have observed gross dilatation, incompetence, and reflux of the ovarian veins in women with PCS and have thus attributed PCS to underlying venous pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/1,11,30,31\">",
"     1,11,30,31",
"    </a>",
"    ]. In this model, anatomic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hormonal factors lead to venous insufficiency of the ovarian veins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    internal iliac veins, resulting in periovarian pelvic varicosities [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/1,16,29,32,33\">",
"     1,16,29,32,33",
"    </a>",
"    ]. Tuboovarian varicoceles have been termed the female equivalent of testicular varicocele [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/11,31,34\">",
"     11,31,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ovarian vein dilatation, stasis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reflux on pelvic venography are common findings in multiparous premenopausal women, and most of these women are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/11,34\">",
"     11,34",
"    </a>",
"    ]. Why these findings are associated with chronic pelvic pain in some women, but not in others, is unclear. A causal relationship has not been proven, but is supported by limited data showing pain relief upon administration of venoconstrictors or ovarian vein",
"    <span class=\"nowrap\">",
"     ligation/embolization.",
"    </span>",
"    For example, a trial that randomly assigned 12 women with PCS to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"     dihydroergotamine",
"    </a>",
"    (a selective venoconstrictor) or saline placebo during an acute attack of pain noted that narrowing of dilated pelvic veins and reduction of venous congestion on venography was associated with diminution in pain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/32\">",
"     32",
"    </a>",
"    ]. Other small studies of women with chronic pelvic pain, venous congestion, and reflux by either Doppler ultrasound",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    venography and no evidence of pelvic pathology at laparoscopy have reported improvement in pain after sclerotherapy, embolization, or venous ligation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/17,33,35-38\">",
"     17,33,35-38",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H25\">",
"     'PCS with vulvar varices'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The higher prevalence of PCS in multiparous women may be related to the 50 percent increase in pelvic vein capacity during pregnancy, which may lead to venous incompetence and reflux in the non-pregnant state [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/1\">",
"     1",
"    </a>",
"    ]. The increased frequency of PCS symptoms on the left side may be due to extrinsic compression of the left renal vein between the aorta and superior mesenteric artery (\"nutcracker phenomenon;\" ie, pelvic congestion, left flank pain, and hematuria) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], or because valvular incompetence of the ovarian vein due to absent ovarian vein valves is more common on the left [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/41\">",
"     41",
"    </a>",
"    ]. In asymptomatic women, ovarian vein valves are missing in 15 percent of women on the left side and 6 percent of women on the right and nearly one-half of these women have valvular incompetence on at least one side.",
"   </p>",
"   <p>",
"    The absence of PCS in menopause has been attributed to the decline in estrogen, which acts as a venous dilator. This hypothesis is supported by observations that pharmacologic or surgical induction of a hypoestrogenic state may result in improvement or resolution of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/1,4,42,43\">",
"     1,4,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diagnosis and diagnostic evaluation PCS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no definitive diagnostic criteria for PCS. In general, the diagnosis is based on a combination of characteristic symptoms, tenderness on physical examination, and documentation of pelvic vein dilatation or incompetence, after exclusion of other causes for these nonspecific findings.",
"   </p>",
"   <p>",
"    The general approach to evaluation of women with chronic pelvic pain is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31864?source=see_link\">",
"     \"Evaluation of chronic pelvic pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Clinical manifestations PCS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCS is characterized by pelvic pain of at least six months duration. It often first manifests during or after a pregnancy, and worsens with subsequent pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/1,12\">",
"     1,12",
"    </a>",
"    ]. The pain varies in severity, but is usually described as a dull ache or heaviness that increases premenstrually; with prolonged standing, postural changes, walking, or activities that increase intraabdominal pressure; and after intercourse (postcoital ache). It is usually unilateral, but can be bilateral or shift from one side to the other. The patient may also complain of sharp exacerbations of pain, dysmenorrhea, deep dyspareunia, and urinary urgency. Gluteal, vulvar,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thigh varices may also be present [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Physical examination PCS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient with characteristic symptoms, the diagnosis is supported by bimanual examination showing marked ovarian tenderness, cervical motion tenderness, and uterine tenderness with direct palpation. In an observational study including 57 women with pelvic pain, the combination of tenderness on abdominal examination over the adnexa and history of postcoital ache was 94 percent sensitive and 77 percent specific for discriminating PCS from other pelvic pathologies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Imaging PCS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging is performed to document the characteristic pelvic venous changes, which support the diagnosis. Although the absence of pelvic venous changes helps to exclude PCS, the presence of these abnormalities is not diagnostic, as incompetent and dilated ovarian veins are common, nonspecific findings. In one study, they were seen on computed tomography in 47 percent of asymptomatic multiparous women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/34\">",
"     34",
"    </a>",
"    ]. In another study, 10 percent of 273 healthy female kidney donors who underwent preoperative abdominal aortography before left nephrectomy had retrograde flow in an incompetent left ovarian vein [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/44\">",
"     44",
"    </a>",
"    ]. About 40 percent of the women with ovarian varices did not have PCS symptoms.",
"   </p>",
"   <p>",
"    In addition, although dilatation of the ovarian vein is necessary but not sufficient for diagnosis, there is no consensus on the optimum cut-off for ovarian vein diameter in PCS, and no validated measure for venous congestion or tortuosity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H731753452\">",
"    <span class=\"h4\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography is the first line imaging study and is used, in part, to exclude pelvic neoplasms and uterine pathology as potential causes of pain. Dilated pelvic veins in the adnexal regions or in the outer one-third of the myometrium (ie, arcuate veins) are common findings on pelvic sonograms.&nbsp;Dilated arcuate veins have no clinical significance, unless associated with other dilated pelvic veins in women with chronic pelvic pain.&nbsp;Focal dilation of these veins could be due to prior instrumentation, trauma, or complications of pregnancy.",
"   </p>",
"   <p>",
"    If PCS is suspected, the ovarian veins should be examined as part of the examination. The diagnosis is supported by visualization of dilatation of the left ovarian vein with reversed caudal flow, presence of tortuous and dilated pelvic venous plexuses (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86201 \" href=\"UTD.htm?11/41/11922\">",
"     image 1",
"    </a>",
"    ), dilated arcuate veins crossing the uterine myometrium, and variable duplex waveform in varicoceles during the Valsalva's maneuver [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/1,11,12,33,46,47\">",
"     1,11,12,33,46,47",
"    </a>",
"    ]. In one study, the mean diameters of the left ovarian vein in 32 patients with presumed PCS and 32 control subjects were 7.9 and 4.9 mm, respectively; the difference was statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasound may not detect venous changes in affected women because imaging is generally performed with the patient in the supine position when the veins are flaccid. Sensitivity is higher if the study is performed with the patient in the upright position or by asking her to Valsalva. Despite these maneuvers, there is still a poor correlation between ultrasound findings and venography for the presence or absence of pelvic varices [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H731753466\">",
"    <span class=\"h4\">",
"     Venography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many investigators recommend selective ovarian and internal iliac venography in patients with symptoms consistent with PCS, with or without vulvar varicosities [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/1,3,4,6,16-18\">",
"     1,3,4,6,16-18",
"    </a>",
"    ]. The procedure involves catheterization of the right and left ovarian veins via a percutaneous femoral or jugular approach. Ovarian venograms in patients with PCS usually demonstrate abnormally dilated ovarian veins (&gt;10 mm in diameter), sluggish blood flow, reflux causing retrograde fill and congestion of the ovarian venous plexus, tortuosity of venous plexuses, uterine venous engorgement, and filling of pelvic veins across the midline (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73402 \" href=\"UTD.htm?15/31/15857\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/1,4,11,16,29,31,33,47,48\">",
"     1,4,11,16,29,31,33,47,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/43/33462?source=see_link&amp;anchor=H1229236866#H1229236866\">",
"     \"Diagnostic evaluation of chronic venous insufficiency\", section on 'Venography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Venous reflux often occurs into the thigh with upright positioning and Valsalva. There also may be evidence of internal iliac vein dilatation and reflux. Depending on the population studied, as many as 80 percent of premenopausal women undergoing venography have pelvic varicosities and venous stasis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/11,30,32,33,44\">",
"     11,30,32,33,44",
"    </a>",
"    ]. Some of these women are asymptomatic, while others have chronic pelvic pain with no other identifiable etiology for their symptoms.",
"   </p>",
"   <p>",
"    Venography is probably more sensitive than ultrasonography since it can be performed in the upright or semi-upright position with a tilting table. The Society for Vascular Surgery (SVS) and the American Venous Forum (AVF) clinical practice guidelines recommend retrograde ovarian and internal iliac venography as the test of choice for the diagnosis of pelvic venous disorders. In addition to making the diagnosis, it provides an opportunity for concurrent therapeutic transcatheter embolization or sclerotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Management of PCS'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Pelvic vein pressures measured at venography have not been correlated with symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H731753473\">",
"    <span class=\"h4\">",
"     Computed tomography and magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) and magnetic resonance (MR) imaging identify tortuous, dilated pelvic and ovarian veins, broad ligament vascular congestion, and ovarian varicoceles better than ultrasound imaging, but are more expensive and do not allow concurrent therapeutic intervention, if indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/3,11,46,47,49-51\">",
"     3,11,46,47,49-51",
"    </a>",
"    ]. They may be indicated as part of the evaluation of pelvic pain to exclude or to further characterize other pelvic pathology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Laparoscopy PCS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristic pelvic venous changes can sometimes be visualized at laparoscopy and laparotomy; however, as discussed above, they are common, nonspecific findings in asymptomatic women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/1,11,12\">",
"     1,11,12",
"    </a>",
"    ]. Laparoscopy is less sensitive than venography for diagnosis of venous congestion. Venographic studies in women following normal laparoscopy for chronic pelvic pain have demonstrated dilatation of the major pelvic veins and congestion in the ovarian plexuses and broad ligaments in more than 80 percent. As with pelvic ultrasonography, diagnostic laparoscopy is generally utilized to exclude other causes of chronic pelvic pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=see_link\">",
"     \"Causes of chronic pelvic pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of chronic pelvic pain is long. The causes and evaluation of chronic pelvic pain are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=see_link\">",
"     \"Causes of chronic pelvic pain in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31864?source=see_link\">",
"     \"Evaluation of chronic pelvic pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Management of PCS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standard approach to treatment of PCS; therapy must be individualized based on symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     PCS without vulvar varices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three randomized clinical trials suggest that medical treatment with gonadotropin-releasing hormone (GnRH) agonists or synthetic progestins effectively decreases pain associated with PCS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial randomly assigned 84 patients to one of four different treatment arms: (1)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      , 50 mg per day; (2) medroxyprogesterone acetate, 50 mg per day, plus psychotherapy; (3) psychotherapy plus placebo; or (4) placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/42\">",
"       42",
"      </a>",
"      ]. Women in the 'medroxyprogesterone acetate' and 'psychotherapy plus medroxyprogesterone acetate' groups were more likely to report significant pain relief than women not receiving any hormonal therapy. When treatment was stopped after four months, the pain recurred in both groups, but returned more rapidly in the medroxyprogesterone acetate group than in the medroxyprogesterone acetate plus psychotherapy group.",
"     </li>",
"     <li>",
"      Another trial randomly assigned 47 women with venographically documented pelvic congestion to six months of treatment with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      (30 mg per day) or depot",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"       goserelin",
"      </a>",
"      (3.6 mg per month) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/28\">",
"       28",
"      </a>",
"      ]. Both groups showed improvement in venography scores and in pelvic pain symptoms, but goserelin more effectively decreased both measures. GnRH agonists cannot be used long-term (ie, more than 6 to 12 months).",
"     </li>",
"     <li>",
"      A third trial randomly assigned 23 subjects with PCS to treatment with a subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"       etonogestrel",
"      </a>",
"      insert or no treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/52\">",
"       52",
"      </a>",
"      ]. After 12 months, pain scores and venography findings significantly improved in the treatment group, but not in controls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite limitations, we suggest a trial of medical therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    insert or GnRH agonist as first-line therapy for treatment of PCS. Patients who are refractory to medical therapy can then consider embolization or sclerotherapy of the ovarian veins with or without the internal iliac veins [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/16,33,38,39,43,47,48,53-57\">",
"     16,33,38,39,43,47,48,53-57",
"    </a>",
"    ], which can be performed at venography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52370 graphicRef66177 \" href=\"UTD.htm?17/58/18339\">",
"     image 3A-B",
"    </a>",
"    ). Pain relief occurs immediately [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/16\">",
"     16",
"    </a>",
"    ]. Other options include laparoscopic or open ligation of the ovarian veins [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/17,26,35,44\">",
"     17,26,35,44",
"    </a>",
"    ] and hysterectomy and bilateral salpingo-oophorectomy in women who have completed childbearing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Invasive treatments for PCS have not been subjected to randomized clinical trials. The efficacy of these therapies is supported only by observational data and case series. The studies generally lack consistency; patients have varied symptoms and lack standardized diagnosis. These reports also lack a control group, involve different venography, embolization and surgical techniques, and fail to provide standardized evaluation of symptoms before and after treatment. The reported technical success rates of embolization for treatment of PCS range from 89 to 100 percent with clinical success rates of 58 to 100 percent over a follow-up period of up to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/16,43,45,55\">",
"     16,43,45,55",
"    </a>",
"    ]. Surgical ligation of the ovarian vein has been associated with improvement in pain in about 75 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/45\">",
"     45",
"    </a>",
"    ]. The effects of hysterectomy are unclear; one study reported improvement after hysterectomy in 75 percent of patients with PCS, while another found no improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     PCS with vulvar varices",
"    </span>",
"    &nbsp;&mdash;&nbsp;If vulvar varices are present, evidence from case reports and small series shows that treatment of ovarian vein reflux leads to reduction in the size of vulvar varicosities [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/17,26\">",
"     17,26",
"    </a>",
"    ]. Surgical approaches and embolization likely result in similar outcomes, although some data are inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/3\">",
"     3",
"    </a>",
"    ]. We prefer embolization to vein ligation because it is safe, well-tolerated, and allows for a minimally invasive approach. Direct vulvar sclerotherapy or local excision of varices can be performed for persistent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/3,18\">",
"     3,18",
"    </a>",
"    ]. One case report utilized ultrasound-guided foam sclerotherapy of vulvar and lower left varicosities to avoid ovarian vein embolization in a patient with ovarian reflux and mild PCS which resulted in improvement in pelvic symptoms and resolution of varicosities [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30681/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <strong>",
"     Vulvar varicosities",
"    </strong>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vulvar varicosities are dilated veins that appear as grape-like clusters of veins on the vulva (\"bag of worms\"). They are caused by venous obstruction, increased pressure, and venous insufficiency and generally appear during pregnancy and regress postpartum. Hormonal and anatomic factors play a role in pathogenesis. They can arise in isolation, in association with",
"      <span class=\"nowrap\">",
"       leg/buttock",
"      </span>",
"      varices, or as part of pelvic congestion syndrome. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Vulvovaginal varicosities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of vulvar varicosities is based on physical examination. Patients should be examined in the supine as well as upright position, which enhances filling of the veins. There is no consensus on indications for imaging. Some clinicians perform magnetic resonance imaging or computed tomography to evaluate pelvic and gonadal veins in all patients with vulvar varicosities and, if imaging is positive, they perform venography if an intervention such as coil embolization is planned. Others omit noninvasive testing and perform diagnostic venography in all patients. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest conservative therapy of vulvar varices during pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pregnant women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For nonpregnant women with persistent bothersome vulvar varices originating from the saphenous vein, we suggest sclerotherapy as first line treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Duplex ultrasonography should be performed prior to the procedure to exclude lower extremity venous insufficiency. If lower extremity venous reflux or obstruction is present, the leg varices should be treated first and the response of vulvar varices assessed. Direct vulvar sclerotherapy or local excision of varices can be performed subsequently, if needed. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Sclerotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with vulvar varices and incompetence of pelvic and gonadal veins, we suggest treatment of ovarian vein reflux first (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Embolization can be performed at the time of diagnostic venography and generally leads to reduction in the size of vulvar varicosities. Local sclerotherapy can be performed subsequently, if needed. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'PCS with vulvar varices'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Pelvic congestion syndrome",
"    </strong>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The etiology of PCS is unclear, there are no definitive diagnostic criteria, and the optimum treatment is uncertain. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Pelvic congestion syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PCS is characterized by a dull ache or heaviness that increases premenstrually; with prolonged standing, postural changes, walking, or activities that increase intraabdominal pressure; and after intercourse (postcoital ache). Dysmenorrhea, deep dyspareunia, and urinary urgency may also occur. Imaging studies in affected women reveal periovarian varicosities. Although the absence of pelvic venous changes helps to exclude PCS, the presence of these abnormalities is not diagnostic, as incompetent and dilated ovarian veins are common, nonspecific findings. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Clinical manifestations PCS'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Imaging PCS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of PCS is based on a combination of characteristic symptoms, tenderness on physical examination, and documentation of pelvic vein dilatation or incompetence, after exclusion of other causes for these nonspecific findings. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnosis and diagnostic evaluation PCS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic laparoscopy is generally utilized to exclude other causes of chronic pelvic pain. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Laparoscopy PCS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite limitations, we suggest a trial of medical therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"       etonogestrel",
"      </a>",
"      insert or gonadotropin-releasing hormone (GnRH) agonist as first line therapy for treatment of PCS (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients who are refractory to medical therapy can then consider embolization or sclerotherapy. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'PCS without vulvar varices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with PCS and vulvar varices, we suggest treatment of ovarian vein reflux first (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This generally leads to reduction in the size of vulvar varicosities. Local sclerotherapy can be performed subsequently, if needed. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'PCS with vulvar varices'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/1\">",
"      Hobbs JT. The pelvic congestion syndrome. Br J Hosp Med 1990; 43:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/2\">",
"      WILSON CE. MANAGEMENT OF VARICOSE VEINS IN PREGNANCY. Nebr State Med J 1964; 49:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/3\">",
"      Scultetus AH, Villavicencio JL, Gillespie DL, et al. The pelvic venous syndromes: analysis of our experience with 57 patients. J Vasc Surg 2002; 36:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/4\">",
"      Ashour MA, Soliman HE, Khougeer GA. Role of descending venography and endovenous embolization in treatment of females with lower extremity varicose veins, vulvar and posterior thigh varices. Saudi Med J 2007; 28:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/5\">",
"      Royle JP, Macafee CA, Beischer NA. An unusual presentation of varicose veins of the vulva. Aust N Z J Obstet Gynaecol 1971; 11:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/6\">",
"      LePage PA, Villavicencio JL, Gomez ER, et al. The valvular anatomy of the iliac venous system and its clinical implications. J Vasc Surg 1991; 14:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/7\">",
"      Dixon JA, Mitchell WA. Venographic and surgical observations in vulvar varicose veins. Surg Gynecol Obstet 1970; 131:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/8\">",
"      Marrocco-Trischitta MM, Nicodemi EM, Nater C, Stillo F. Management of congenital venous malformations of the vulva. Obstet Gynecol 2001; 98:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/9\">",
"      Ninia JG, Goldberg TL. Treatment of vulvar varicosities by injection-compression sclerotherapy and a pelvic supporter. Obstet Gynecol 1996; 87:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/10\">",
"      Veltman LL, Ostergard DR. Thrombosis of vulvar varicosities during pregnancy. Obstet Gynecol 1972; 39:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/11\">",
"      Beard RW, Highman JH, Pearce S, Reginald PW. Diagnosis of pelvic varicosities in women with chronic pelvic pain. Lancet 1984; 2:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/12\">",
"      Beard RW, Reginald PW, Wadsworth J. Clinical features of women with chronic lower abdominal pain and pelvic congestion. Br J Obstet Gynaecol 1988; 95:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/13\">",
"      Venbrux AC, Lambert DL. Embolization of the ovarian veins as a treatment for patients with chronic pelvic pain caused by pelvic venous incompetence (pelvic congestion syndrome). Curr Opin Obstet Gynecol 1999; 11:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/14\">",
"      Bell D, Kane PB, Liang S, et al. Vulvar varices: an uncommon entity in surgical pathology. Int J Gynecol Pathol 2007; 26:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/15\">",
"      Herman AR, Morello F, Strickland JL. Vulvar venous malformations in an 11-year-old girl: a case report. J Pediatr Adolesc Gynecol 2004; 17:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/16\">",
"      Cordts PR, Eclavea A, Buckley PJ, et al. Pelvic congestion syndrome: early clinical results after transcatheter ovarian vein embolization. J Vasc Surg 1998; 28:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/17\">",
"      Mathis BV, Miller JS, Lukens ML, Paluzzi MW. Pelvic congestion syndrome: a new approach to an unusual problem. Am Surg 1995; 61:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/18\">",
"      Giannoukas AD, Dacie JE, Lumley JS. Recurrent varicose veins of both lower limbs due to bilateral ovarian vein incompetence. Ann Vasc Surg 2000; 14:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/19\">",
"      Wang S, Lang JH, Zhou HM. Venous malformations of the female lower genital tract. Eur J Obstet Gynecol Reprod Biol 2009; 145:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/20\">",
"      Cebesoy FB, Kutlar I, Aydin A. A rare mass formation of the vulva: giant cavernous hemangioma. J Low Genit Tract Dis 2008; 12:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/21\">",
"      da Silva BB, Lopes-Costa PV, Furtado-Veloso AM, Borges RS. Vulvar epithelioid hemangioendothelioma. Gynecol Oncol 2007; 105:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/22\">",
"      Bava GL, Dalmonte P, Oddone M, Rossi U. Life-threatening hemorrhage from a vulvar hemangioma. J Pediatr Surg 2002; 37:E6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/23\">",
"      Lazarou G, Goldberg MI. Vulvar arteriovenous hemangioma. A case report. J Reprod Med 2000; 45:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/24\">",
"      Gearhart PA, Levin PJ, Schimpf MO. Expanding on earlier findings A vulvar varicosity grew larger with each pregnancy. Am J Obstet Gynecol 2011; 204:89.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/25\">",
"      Rasmussen OO, Hamilton Jakobsen B. Post-partum persisting pudendal varicose veins--effect of local excision. Vasa 1987; 16:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/26\">",
"      Leung SW, Leung PL, Yuen PM, Rogers MS. Isolated vulval varicosity in the non-pregnant state: a case report with review of the treatment options. Aust N Z J Obstet Gynaecol 2005; 45:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/27\">",
"      Beard RW, Reginald P, Pearce S. Pelvic pain in women. Br Med J (Clin Res Ed) 1987; 294:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/28\">",
"      Soysal ME, Soysal S, Vicdan K, Ozer S. A randomized controlled trial of goserelin and medroxyprogesterone acetate in the treatment of pelvic congestion. Hum Reprod 2001; 16:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/29\">",
"      Fassiadis N. Treatment for pelvic congestion syndrome causing pelvic and vulvar varices. Int Angiol 2006; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/30\">",
"      TAYLOR HC Jr. Vascular congestion and hyperemia; their effect on structure and function in the female reproductive system. Am J Obstet Gynecol 1949; 57:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/31\">",
"      Hobbs JT. The pelvic congestion syndrome. Practitioner 1976; 216:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/32\">",
"      Reginald PW, Beard RW, Kooner JS, et al. Intravenous dihydroergotamine to relieve pelvic congestion with pain in young women. Lancet 1987; 2:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/33\">",
"      Tropeano G, Di Stasi C, Amoroso S, et al. Ovarian vein incompetence: a potential cause of chronic pelvic pain in women. Eur J Obstet Gynecol Reprod Biol 2008; 139:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/34\">",
"      Rozenblit AM, Ricci ZJ, Tuvia J, Amis ES Jr. Incompetent and dilated ovarian veins: a common CT finding in asymptomatic parous women. AJR Am J Roentgenol 2001; 176:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/35\">",
"      Gargiulo T, Mais V, Brokaj L, et al. Bilateral laparoscopic transperitoneal ligation of ovarian veins for treatment of pelvic congestion syndrome. J Am Assoc Gynecol Laparosc 2003; 10:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/36\">",
"      Edwards RD, Robertson IR, MacLean AB, Hemingway AP. Case report: pelvic pain syndrome--successful treatment of a case by ovarian vein embolization. Clin Radiol 1993; 47:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/37\">",
"      Maleux G, Stockx L, Wilms G, Marchal G. Ovarian vein embolization for the treatment of pelvic congestion syndrome: long-term technical and clinical results. J Vasc Interv Radiol 2000; 11:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/38\">",
"      Venbrux AC, Chang AH, Kim HS, et al. Pelvic congestion syndrome (pelvic venous incompetence): impact of ovarian and internal iliac vein embolotherapy on menstrual cycle and chronic pelvic pain. J Vasc Interv Radiol 2002; 13:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/39\">",
"      d'Archambeau O, Maes M, De Schepper AM. The pelvic congestion syndrome: role of the \"nutcracker phenomenon\" and results of endovascular treatment. JBR-BTR 2004; 87:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/40\">",
"      Menard MT. Nutcracker syndrome: when should it be treated and how? Perspect Vasc Surg Endovasc Ther 2009; 21:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/41\">",
"      Ahlberg NE, Bartley O, Chidekel N. Right and left gonadal veins. An anatomical and statistical study. Acta Radiol Diagn (Stockh) 1966; 4:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/42\">",
"      Farquhar CM, Rogers V, Franks S, et al. A randomized controlled trial of medroxyprogesterone acetate and psychotherapy for the treatment of pelvic congestion. Br J Obstet Gynaecol 1989; 96:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/43\">",
"      Chung MH, Huh CY. Comparison of treatments for pelvic congestion syndrome. Tohoku J Exp Med 2003; 201:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/44\">",
"      Belenky A, Bartal G, Atar E, et al. Ovarian varices in healthy female kidney donors: incidence, morbidity, and clinical outcome. AJR Am J Roentgenol 2002; 179:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/45\">",
"      Tu FF, Hahn D, Steege JF. Pelvic congestion syndrome-associated pelvic pain: a systematic review of diagnosis and management. Obstet Gynecol Surv 2010; 65:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/46\">",
"      Park SJ, Lim JW, Ko YT, et al. Diagnosis of pelvic congestion syndrome using transabdominal and transvaginal sonography. AJR Am J Roentgenol 2004; 182:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/47\">",
"      Freedman J, Ganeshan A, Crowe PM. Pelvic congestion syndrome: the role of interventional radiology in the treatment of chronic pelvic pain. Postgrad Med J 2010; 86:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/48\">",
"      Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg 2011; 53:2S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/49\">",
"      Desimpelaere JH, Seynaeve PC, Hagers YM, et al. Pelvic congestion syndrome: demonstration and diagnosis by helical CT. Abdom Imaging 1999; 24:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/50\">",
"      Nascimento AB, Mitchell DG, Holland G. Ovarian veins: magnetic resonance imaging findings in an asymptomatic population. J Magn Reson Imaging 2002; 15:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/51\">",
"      Meneses LQ, Uribe S, Tejos C, et al. Using magnetic resonance phase-contrast velocity mapping for diagnosing pelvic congestion syndrome. Phlebology 2011; 26:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/52\">",
"      Shokeir T, Amr M, Abdelshaheed M. The efficacy of Implanon for the treatment of chronic pelvic pain associated with pelvic congestion: 1-year randomized controlled pilot study. Arch Gynecol Obstet 2009; 280:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/53\">",
"      Kwon SH, Oh JH, Ko KR, et al. Transcatheter ovarian vein embolization using coils for the treatment of pelvic congestion syndrome. Cardiovasc Intervent Radiol 2007; 30:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/54\">",
"      Pieri S, Agresti P, Morucci M, de' Medici L. Percutaneous treatment of pelvic congestion syndrome. Radiol Med 2003; 105:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/55\">",
"      Sichlau MJ, Yao JS, Vogelzang RL. Transcatheter embolotherapy for the treatment of pelvic congestion syndrome. Obstet Gynecol 1994; 83:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/56\">",
"      Kim HS, Malhotra AD, Rowe PC, et al. Embolotherapy for pelvic congestion syndrome: long-term results. J Vasc Interv Radiol 2006; 17:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/57\">",
"      Ghosh A, Shafie-Pour H, Ayers KJ. Laparoscopic sclerotherapy in a case of pelvic congestion syndrome. BJOG 2006; 113:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/58\">",
"      Beard RW, Kennedy RG, Gangar KF, et al. Bilateral oophorectomy and hysterectomy in the treatment of intractable pelvic pain associated with pelvic congestion. Br J Obstet Gynaecol 1991; 98:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30681/abstract/59\">",
"      Paraskevas P. Successful ultrasound-guided foam sclerotherapy for vulval and leg varicosities secondary to ovarian vein reflux: a case study. Phlebology 2011; 26:29.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5420 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-CCB85E928E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_61_30681=[""].join("\n");
var outline_f29_61_30681=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VULVOVAGINAL VARICOSITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathogenesis/pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Sclerotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Ligation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PELVIC CONGESTION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Epidemiology PCS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pathogenesis/pathology PCS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diagnosis and diagnostic evaluation PCS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Clinical manifestations PCS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Physical examination PCS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Imaging PCS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H731753452\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H731753466\">",
"      Venography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H731753473\">",
"      Computed tomography and magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Laparoscopy PCS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Management of PCS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - PCS without vulvar varices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - PCS with vulvar varices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5420\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5420|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/41/11922\" title=\"diagnostic image 1\">",
"      Multiple tortuous pelvic veins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/31/15857\" title=\"diagnostic image 2\">",
"      Pelvic congestion syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/56/42895\" title=\"diagnostic image 3A\">",
"      Pelvic congestion syndrome 11a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/26/13743\" title=\"diagnostic image 3B\">",
"      Pelvic congestion syndrome 11b",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5420|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/10/38048\" title=\"figure 1\">",
"      Vulvar varicosities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5420|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/28/25039\" title=\"picture 1\">",
"      Vulvar varicosity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=related_link\">",
"      Causes of chronic pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31321?source=related_link\">",
"      Classification, clinical features and diagnosis of inguinal and femoral hernias in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/43/33462?source=related_link\">",
"      Diagnostic evaluation of chronic venous insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20618?source=related_link\">",
"      Differential diagnosis of vulvar lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22375?source=related_link\">",
"      Disorders of Bartholin gland",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=related_link\">",
"      Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44071?source=related_link\">",
"      Evaluation and management of lower genital tract trauma in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31864?source=related_link\">",
"      Evaluation of chronic pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30408?source=related_link\">",
"      Interventional radiology in management of gynecological disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17031?source=related_link\">",
"      Laser and light therapy of lower extremity telangiectasias, reticular veins and small varicose veins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13514?source=related_link\">",
"      Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16455?source=related_link\">",
"      Management of hematomas incurred as a result of obstetrical delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/29/21977?source=related_link\">",
"      Open surgical techniques for lower extremity vein ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=related_link\">",
"      Overview and management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30809?source=related_link\">",
"      Radiofrequency ablation for the treatment of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_61_30682="Secondary prevention of stroke: Risk factor reduction";
var content_f29_61_30682=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Secondary prevention of stroke: Risk factor reduction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/61/30682/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/61/30682/contributors\">",
"     Karen L Furie, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/61/30682/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/61/30682/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/61/30682/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/61/30682/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/61/30682/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of treatable risk factors that contribute to the development and progression of atherosclerotic cerebrovascular disease is important for reducing the risk of ischemic stroke. This topic will review the risk factor management of patients with atherosclerotic cerebrovascular disease, with a focus on secondary prevention in patients who have a history of transient ischemic attack or ischemic stroke, or are considered to have a high risk of ischemic stroke due to the presence of coronary heart disease or diabetes.",
"   </p>",
"   <p>",
"    The role of secondary prevention for cardiovascular disease other than stroke is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTOR IMPACT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major treatable risk factors for cerebrovascular atherosclerotic disease are similar to those for coronary atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Smoking",
"     </li>",
"     <li>",
"      Dyslipidemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk is particularly increased in patients with two or more of these risk factors (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?10/25/10642?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/43/9906?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). As an example, one study of 3998 subjects found that the incidence of mild (25 to 49 percent) or severe carotid stenosis (&ge;50 percent) increased as the number of risk factors increased, and was higher in men than women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      With no risk factors the incidence of a severe stenosis was 2.4 and 0.6 percent",
"     </li>",
"     <li>",
"      When one risk factor was present the incidence was 6.7 and 1.5 percent",
"     </li>",
"     <li>",
"      When two risk factors were present the incidence was 10.7 and 2.7 percent",
"     </li>",
"     <li>",
"      When three risk factors were present the incidence was 18.6 and 5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, even when all of these factors are considered, they only account for 40 percent of the variability in the extent of carotid atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/3\">",
"     3",
"    </a>",
"    ]. The multicenter Family Health Study found an age-, sex-, and ethnicity-adjusted odds ratio for stroke of 2.0 for a positive paternal and 1.4 for a positive maternal history of stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/7\">",
"     7",
"    </a>",
"    ]. The relative roles of genetic and environmental factors could not be ascertained. Other studies, however, have suggested that inheritable factors play an important role [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. As an example, being an identical twin, as compared with a dizygotic twin, of a stroke victim increases the risk of stroke fivefold [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/8\">",
"     8",
"    </a>",
"    ]. Another predisposing factor appears to be black race [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Control of atherosclerotic risk factors is important for the primary prevention of stroke and in patients who already have evidence of cerebrovascular disease (eg, those who have undergone carotid endarterectomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/11\">",
"     11",
"    </a>",
"    ]. Control of risk factors also reduces the risk of coronary events, a common comorbidity in patients with cerebrovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension, which promotes the formation of atherosclerotic lesions, is the single most important treatable risk factor for stroke.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epidemiologic studies of treated and untreated patients reveal that there is a gradually increasing incidence of cardiovascular mortality as the blood pressure rises above",
"      <span class=\"nowrap\">",
"       110/75",
"      </span>",
"      mmHg (",
"      <a class=\"graphic graphic_figure graphicRef66793 graphicRef75106 \" href=\"UTD.htm?35/1/35858\">",
"       figure 1A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Approximately 60 percent of strokes in men and women of all ages are attributed to hypertension.",
"     </li>",
"     <li>",
"      Hypertension is associated with an increased likelihood of subclinical or silent stroke, which in turn has been linked with an elevated risk of vascular dementia and recurrent stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/14-16\">",
"       14-16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In addition to mean blood pressure elevation, there is mounting evidence that visit-to-visit variability in systolic blood pressure is itself an independent risk factor for stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these observations alone do not prove a causal relationship, since increasing blood pressure could be a marker for other risk factors such as increasing body weight, dyslipidemia, glucose intolerance, and the metabolic syndrome. The best evidence supporting a causal role of increasing blood pressure in cardiovascular complications comes from studies that show outcome reduction in the risk of recurrent stroke with antihypertensive therapy. This evidence is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17305?source=see_link\">",
"     \"Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines issued in 2011 by the American Heart Association and American Stroke Association recommend antihypertensive treatment for all patients with ischemic stroke and transient ischemic attack who are more than 24 hours from symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/19\">",
"     19",
"    </a>",
"    ]. In patients with acute ischemic stroke, it is important not to lower the blood pressure too quickly. The management of blood pressure in the setting of acute stroke is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link&amp;anchor=H14#H14\">",
"     \"Initial assessment and management of acute stroke\", section on 'Blood pressure management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lifestyle modifications that have been associated with blood pressure reductions should be included as part of the antihypertensive regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/19\">",
"     19",
"    </a>",
"    ]. Important modifications include weight loss, salt restriction, a diet rich in fruits, vegetables, and low-fat dairy products, regular aerobic physical activity, and limited alcohol consumption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SMOKING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking is associated with an increased risk for all stroke subtypes and has a strong, dose-response relationship for both ischemic stroke and subarachnoid hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/20-25\">",
"     20-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Nurses' Health Study, smokers had a relative risk of stroke of 2.58 compared with never smokers [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/21\">",
"       21",
"      </a>",
"      ]. Evaluation of former smokers found that the excess risk disappeared within two to four years after the cessation of smoking.",
"     </li>",
"     <li>",
"      In the Framingham Heart Study, the odds ratio for moderate carotid stenosis was 1.08 for each five pack-years of smoking [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 10,938 normotensive subjects in a prospective Swedish cohort study, about 39 percent of strokes were attributable to smoking [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no randomized controlled trials of smoking cessation for stroke prevention. However, observational studies have shown that the elevated risk of stroke due to smoking declines after quitting and is eliminated by five-years later [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/21,25,26\">",
"     21,25,26",
"    </a>",
"    ]. Therefore, national guidelines recommend smoking cessation for patients with stroke or transient ischemic attack (TIA) who have smoked in the year prior to the event and suggest avoidance of environmental tobacco smoke [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIABETES MELLITUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with diabetes mellitus have approximately twice the risk of ischemic stroke compared with those without diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. Dyslipidemia, endothelial dysfunction, and platelet and coagulation abnormalities are among the risk factors that may promote the development of carotid atherosclerosis in diabetics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Impaired glucose tolerance may be a risk factor for ischemic stroke in patients with a history of transient ischemic attack (TIA) or minor ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/31\">",
"     31",
"    </a>",
"    ]. It may also be a risk factor for carotid atherosclerosis, as illustrated by studies in nondiabetics showing that elevated serum hemoglobin A1C is associated with an increased risk of carotid plaque development [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strict glycemic control reduces the risk of microvascular complications (eg, retinopathy, nephropathy, and neuropathy) in patients with diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link&amp;anchor=H2#H2\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Hyperglycemia and Microvascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, randomized controlled trials have not demonstrated a consistent beneficial effect of intensive glucose-lowering therapy or lifestyle modification on macrovascular outcomes (eg, cardiovascular events and death) in patients with type 2 diabetes. This issue is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link&amp;anchor=H9#H9\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Macrovascular disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\", section on 'Intensive lifestyle modification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with diabetes and ischemic stroke or TIA, guidelines issued in 2011 by the American Heart Association and American Stroke Association",
"    <span class=\"nowrap\">",
"     (AHA/ASA)",
"    </span>",
"    recommend the use of existing guidelines for glycemic control and blood pressure targets [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link&amp;anchor=H19#H19\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Glycemic targets'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Metabolic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolic syndrome (defined as the presence of three or more components that include high fasting glucose, hypertension, low high-density lipoprotein, and abdominal obesity) is considered to be a prediabetic condition linked to insulin resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unclear if the metabolic syndrome is an independent risk factor for ischemic stroke beyond the sum of its individual components, and the available evidence is conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/34-41\">",
"     34-41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective cohort study of 14,284 patients with coronary heart disease found that the risk for stroke or TIA was independently associated with the presence of metabolic syndrome without diabetes, as well as with frank diabetes (odds ratios 1.5 and 2.3, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another prospective population-based cohort study followed 3298 stroke-free subjects (44 percent of whom had metabolic syndrome) for a mean of 6.4 years [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/39\">",
"       39",
"      </a>",
"      ]. After adjusting for age, ethnicity, sex, socioeconomic status, and other vascular risk factors, the metabolic syndrome was associated with an increased risk of ischemic stroke (hazard ratio 1.5, 95% CI 1.1-2.2).",
"     </li>",
"     <li>",
"      In the prospective ARIC study of 14,993 middle-aged subjects who were stroke-free at baseline, metabolic syndrome was present in 39 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/41\">",
"       41",
"      </a>",
"      ]. There was a dose-response relationship between the number of metabolic syndrome components and risk of ischemic stroke. Elevated blood pressure and elevated fasting glucose were the two components that conveyed the highest risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The utility of the metabolic syndrome to predict stroke risk does not appear to improve upon more conventional assessments such as the Framingham Risk Score (FRS). In a prospective study of 5128 middle-aged men with no history of stroke or coronary heart disease, presence of the metabolic syndrome was associated with a significant increase in stroke risk, but the FRS was significantly more effective for predicting stroke than the number of metabolic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link&amp;anchor=H9#H9\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\", section on 'Framingham risk scores'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although it is not clearly established as an independent stroke risk factor, it seems reasonable to consider treating metabolic syndrome in order to reduce stroke risk. However, there are no data to confirm that such treatment is effective for stroke risk reduction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link&amp;anchor=H15#H15\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\", section on 'Therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stroke guidelines issued by the",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    in 2011 note that the utility of screening patients for the metabolic syndrome after stroke has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/19\">",
"     19",
"    </a>",
"    ]. However, for patients who are screened and classified as having the metabolic syndrome, the",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines state that management should include counseling for lifestyle modification (diet, exercise, and weight loss) for vascular risk reduction. In addition, preventive care should include appropriate treatment for individual components of the metabolic syndrome, particularly hypertension and dyslipidemia, which are also stroke risk factors. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Hypertension'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Dyslipidemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients with ischemic stroke or TIA who are capable of engaging in physical activity, the 2011",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines note that at least 30 minutes of moderate intensity exercise, defined as vigorous activity sufficient to break a sweat or noticeably raise the heart rate (eg, walking briskly, using an exercise bicycle) one to three times a week may be considered to reduce risk factors and comorbid conditions associated with an increased likelihood of recurrent stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with glycemic control, there are no data to confirm that weight reduction reduces the risk of recurrent stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/19\">",
"     19",
"    </a>",
"    ]. However, weight reduction is potentially beneficial for improved control of other important parameters, including blood pressure, blood glucose, and serum lipid levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DYSLIPIDEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperlipidemia is a major risk factor for coronary heart disease (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    ). However, the relationship between the serum cholesterol concentration and stroke incidence appears to be more complex, in that cholesterol is an established risk factor for atherosclerosis, but appears to be only a weak risk factor for ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ischemic and hemorrhagic stroke risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiologic evidence regarding the risk of ischemic stroke attributable to cholesterol is inconsistent and conflicting, as illustrated by the following reports.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A review of 45 prospective observational cohort studies involving 450,000 subjects with 5 to 30 years of follow-up (mean 16 years) included data from 13,397 subjects who had a stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/45\">",
"       45",
"      </a>",
"      ]. Most of these were fatal strokes, but about one-quarter were from studies that included both fatal and non-fatal strokes. After adjustment for age, there was no association between serum cholesterol and stroke except in those under 45 years of age. This lack of association was not influenced by adjustment for sex, diastolic blood pressure, history of coronary disease, or ethnicity. However, stroke types were not available for analysis, and the observed lack of association between cholesterol and stroke in this study may have masked a positive association for ischemic stroke combined with a negative association for hemorrhagic stroke. An additional bias may have come from the large proportion of studies that looked at only fatal strokes.",
"     </li>",
"     <li>",
"      Studies that have examined ischemic and hemorrhagic stroke types have generally found a weak but positive association of cholesterol with ischemic stroke and an inverse association of cholesterol with hemorrhagic stroke. As examples, one study found that serum cholesterol levels under 4.14",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      (160",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      increased the risk of fatal intracranial hemorrhage, while levels above 7.23",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      (280",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      increased the risk of death from ischemic stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/46\">",
"       46",
"      </a>",
"      ], and a later prospective community-based study found that very high total cholesterol levels above 8",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      (309",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      were associated with an increased risk of nonhemorrhagic stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/47\">",
"       47",
"      </a>",
"      ]. However, a study of Asian subjects found that decreasing cholesterol levels showed only a nonsignificant trend toward a decreased risk of ischemic stroke and an increased risk of hemorrhagic stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study that compared cases of ischemic stroke (n = 1242) and hemorrhagic stroke (n = 313) with controls (n = 6455), elevated total cholesterol and lower HDL levels were associated with an increased risk of ischemic stroke, especially for large artery atherosclerotic and lacunar stroke subtypes [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/49\">",
"       49",
"      </a>",
"      ]. The study excluded nonhypertensive males, limiting the strength of the findings.",
"     </li>",
"     <li>",
"      A meta-analysis of lipid-lowering therapy found that dietary or drug intervention (fibrates and resins) other than statins did not significantly reduce the risk of stroke in subjects with elevated cholesterol levels [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/47,51\">",
"       47,51",
"      </a>",
"      ], but not all [",
"      <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/52,53\">",
"       52,53",
"      </a>",
"      ], prospective epidemiologic studies suggested that hypertriglyceridemia is a moderate risk factor for ischemic stroke.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, the large epidemiologic studies and clinical trials have not consistently found dyslipidemia to be a strong risk factor for ischemic stroke. However, most of these studies did not analyze stroke in terms of the various etiologic subtypes (eg, large vessel, lacunar, cardioembolic), but rather lumped these heterogeneous mechanisms into a single category of ischemic stroke, thereby weakening the ability to find an association [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is some evidence suggesting that dyslipidemia may be a risk factor for large artery atherosclerotic and lacunar stroke subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/49\">",
"     49",
"    </a>",
"    ]. In addition, the strong association between cholesterol and carotid atherosclerosis supports the role of cholesterol in the pathogenesis of large artery ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/54\">",
"     54",
"    </a>",
"    ]. However, more data are needed regarding the relationship of dyslipidemia to specific stroke mechanisms.",
"   </p>",
"   <p>",
"    The relationship of cholesterol levels and statin therapy with intracerebral hemorrhage is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link&amp;anchor=H8#H8\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Statin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with hyperlipidemia, treatment with HMG CoA reductase inhibitors (statins) decreases the risk of stroke, while lipid lowering by other means (eg, fibrates, resins, diet) has no significant impact on stroke incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/50,55\">",
"     50,55",
"    </a>",
"    ]. Therefore, it seems plausible that the protective effects of statins are not mediated by cholesterol lowering [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/44\">",
"     44",
"    </a>",
"    ], but by anti-atherothrombotic properties [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Potential mechanisms'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statins reduce the risk of both initial and recurrent stroke. This conclusion is supported by a meta-analysis of randomized controlled trials with more than 165,000 participants published through December 2008 that evaluated statin treatment in combination with other preventive strategies for all stroke (ischemic and hemorrhagic), including both primary and secondary prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations were made [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/57\">",
"     57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with control assignment, statin treatment reduced the risk of all stroke by 18 percent (95% CI 13-23 percent).",
"     </li>",
"     <li>",
"      In 10 trials with over 83,000 patients, statins did NOT increase the risk of hemorrhagic stroke (relative risk [RR] 1.03, 95% CI 0.75-1.41). However, in a subgroup of patients with prior symptomatic cerebrovascular disease, most from the SPARCL trial, there was an increased risk of hemorrhagic stroke (RR 1.73, 95% CI 1.19-2.5)",
"     </li>",
"     <li>",
"      In the only trial (SPARCL) designed to evaluate statins for secondary stroke prevention, intense reduction of LDL significantly reduced the risk of noncardioembolic recurrent stroke (RR 0.84), as discussed in the following section.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     SPARCL trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SPARCL trial is the first to show that statin treatment decreases the risk of recurrent ischemic stroke among patients with a history of stroke or TIA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The trial randomly assigned 4731 ambulatory patients with no known coronary heart disease (CHD) who had a stroke or TIA within one to six months to treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/58\">",
"     58",
"    </a>",
"    ]. Patients were required to have a baseline low-density lipoprotein cholesterol (LDL-C) of 100 to 190",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6 to 4.9",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    The mean baseline LDL-C and total cholesterol levels were about 133 and 212",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4 and 5.5",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Patients with hemorrhagic stroke were included if they were deemed to be at risk for ischemic stroke or CHD. Patients were excluded if they had atrial fibrillation, other cardiac sources of embolism, or subarachnoid hemorrhage.",
"   </p>",
"   <p>",
"    At a median follow-up of 4.9 years, the following observations were noted for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    treatment compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/58\">",
"     58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       Atorvastatin",
"      </a>",
"      was associated with a mean reduction in LDL-C of 56",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.4",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       Atorvastatin",
"      </a>",
"      was associated with a reduction in fatal or nonfatal stroke, the primary endpoint (11.2 versus 13.1 percent, adjusted hazard ratio [HR] 0.84, 95% CI 0.71-0.99, absolute risk reduction at five years 2.2 percent, 95% CI 0.2-4.2 percent).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       Atorvastatin",
"      </a>",
"      was associated with a significant reduction in all coronary events (5.2 versus 8.6 percent, HR 0.58, 95% CI 0.46-0.73) and all cardiovascular events (22.4 versus 29 percent, HR 0.74, 95% CI 0.66-0.83).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       Atorvastatin",
"      </a>",
"      was associated with a nonsignificant reduction in cardiovascular death (3.3 versus 4.1 percent, HR 0.78, 95% CI 0.58-1.06). There was no difference between the atorvastatin and placebo groups in overall mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the significant overall benefit for stroke risk reduction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    , a post hoc analysis found that atorvastatin was associated with an increased risk of hemorrhagic stroke (HR 1.66, 95% CI 1.08-2.55) and a reduced risk of ischemic stroke (HR 0.78, 95% CI 0.66-0.94). While these data do not establish that statin therapy increases the risk of hemorrhagic stroke in all patients with prior stroke or prior hemorrhagic stroke, they are congruent with epidemiologic evidence that suggests an inverse association between cholesterol and hemorrhagic stroke. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Ischemic and hemorrhagic stroke risk'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link&amp;anchor=H8#H8\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     HPS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HPS study enrolled 3,280 adults with cerebrovascular disease who had previous nondisabling ischemic stroke, TIA,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a history of carotid endarterectomy or angioplasty, but excluded patients who had stroke within six months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/59\">",
"     59",
"    </a>",
"    ]. An additional 17,256 subjects with other occlusive arterial disease or diabetes were also enrolled. The average LDL-C at study entry was 131",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    though 33 percent had baseline LDL-C &lt;116",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&lt;3",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Subjects were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or placebo. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On average",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      therapy was associated with a reduction in LDL-cholesterol of 39",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       Simvastatin",
"      </a>",
"      treatment was associated with a significant reduction in all first stroke compared with placebo (4.3 versus 5.7 percent), reflecting a 28 percent reduction in ischemic strokes and no apparent difference in hemorrhagic strokes. The reduction in stroke became significant by the second year of the five-year study duration.",
"     </li>",
"     <li>",
"      There was no significant reduction of stroke rate with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      treatment among 3,280 subjects with preexisting cerebrovascular disease. However, in both the subgroup of preexisting cerebrovascular diseases and in the entire population, simvastatin therapy was associated with a significant reduction in the rate of any major vascular event.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The HPS findings showed that statin therapy is associated with a substantial reduction in ischemic stroke, regardless of age, gender, or blood lipid concentration when treatment is initiated. Furthermore, statin therapy reduced the risk of major vascular events among people who have had a previous stroke.",
"   </p>",
"   <p>",
"    The lack of benefit with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    for secondary stroke prevention in the HPS subjects was surprising. Possible explanations for this discrepant result include the post-hoc subgroup analysis itself, which may have been more prone to statistical variation, and the combined analysis of ischemic, hemorrhagic, and non-classified types of stroke as \"stroke\" [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/60\">",
"     60",
"    </a>",
"    ]. Another possible explanation is that HPS subjects were enrolled at a mean of 4.3 years after their stroke or TIA, a time point when the likelihood of stroke recurrence was probably less than the likelihood of coronary events [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Utility despite normal cholesterol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even patients with \"average\" serum cholesterol concentrations appear to benefit from statin therapy in terms of stroke reduction. This was demonstrated in the SPARCL trial [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/58\">",
"     58",
"    </a>",
"    ], where the mean baseline LDL-C and total cholesterol levels were 133 and 212",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4 and 5.5",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    respectively, and in the HPS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/59\">",
"     59",
"    </a>",
"    ], where the mean baseline LDL-C and total cholesterol levels were 131 and 224",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4 and 5.8",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    respectively.",
"   </p>",
"   <p>",
"    Benefit with statin treatment was also seen in the CARE trial, which included 4159 patients with a history of a myocardial infarction in the previous two years who had mean LDL-C and total cholesterol serum concentrations of 139 and 209",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.6 and 5.4",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/62\">",
"     62",
"    </a>",
"    ]. In addition to a reduction in coronary events, therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    was associated with significant reductions in the frequency of stroke (2.6 versus 3.8 percent) and of stroke plus transient ischemic attacks (4.4 versus 6.0 percent).",
"   </p>",
"   <p>",
"    A similar reduction in stroke was noted with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    (10 mg) in the ASCOT-LLA trial that looked at high-risk patients with hypertension but relatively normal cholesterol levels who did not have coronary heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/63\">",
"     63",
"    </a>",
"    ]. The rate of fatal and nonfatal stroke was significantly lower with atorvastatin than placebo (5.4 versus 7.4 events per 1000 patient-years). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\", section on 'ASCOT-LLA trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It should be noted that the mechanism of stroke was poorly characterized in several of these trials. It is possible that reducing the risk of myocardial infarction reduced the risk of cardioembolic stroke. The investigators did not prove that statins had an impact upon the rate of large vessel atherothrombotic or lacunar infarcts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Potential mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;To summarize, the totality of evidence presents a paradox: long-term treatment with statins reduces the risk of stroke, but hypercholesterolemia is not a strong risk factor for stroke.",
"   </p>",
"   <p>",
"    An explanation for this apparent paradox is becoming clear as we continue to learn more about the mechanism of benefit of statins. In addition to their cholesterol lowering properties, statins also have a role in plaque stabilization, reducing inflammation, slowing carotid arterial disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/61,64,65\">",
"     61,64,65",
"    </a>",
"    ], improving endothelial function, and reducing embolic stroke by prevention of myocardial infarction and left ventricular dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;While treatment with statins decreases the risk of recurrent ischemic stroke in patients with hyperlipidemia, the available evidence suggests that lipid lowering by other means (eg, fibrates, bile acid sequestrants, niacin, diet) has no significant impact on the secondary prevention of stroke or prevention of other cardiovascular events. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7800?source=see_link\">",
"     \"Lipid lowering with fibric acid derivatives\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link\">",
"     \"Lipid lowering with drugs other than statins and fibrates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link\">",
"     \"Lipid lowering with diet or dietary supplements\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ANTITHROMBOTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the major exception of patients with atrial fibrillation, where anticoagulation is superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , randomized clinical trials have found no statistically significant difference between aspirin and anticoagulant therapy for reducing the risk of recurrent ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/66\">",
"     66",
"    </a>",
"    ]. However, the risk of major hemorrhage is higher with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    than with aspirin. In addition, warfarin therapy is more complicated to administer than antiplatelet therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since antiplatelet agents are effective for the prevention of recurrent ischemic stroke in patients with a history of noncardioembolic ischemic stroke or TIA of atherothrombotic, lacunar (small vessel occlusive), or cryptogenic type, nearly all such patients should be treated with an antiplatelet agent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link\">",
"       \"Antiplatelet therapy for secondary prevention of stroke\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Long-term anticoagulation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      should be considered as prevention for patients with chronic nonvalvular atrial fibrillation who have risk factors for stroke. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Short-term (eg, three to six months) anticoagulation is the most widely used treatment for the prevention of ischemic stroke related to dissection of cervical or intracranial large arteries. However, no randomized trials have compared antiplatelet therapy with anticoagulation for this condition. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32281?source=see_link&amp;anchor=H7#H7\">",
"       \"Secondary prevention for specific causes of ischemic stroke and transient ischemic attack\", section on 'Dissection'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OTHER FACTORS INFLUENCING RISK",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Alcohol intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol affects the risk of stroke in contradictory directions depending upon level of consumption, type of stroke, and possibly ethnicity. Light drinking (one to two drinks per day) is associated with a reduced risk of stroke, while heavy drinking is associated with an increased risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=see_link&amp;anchor=H11#H11\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\", section on 'Stroke risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    National guidelines from the American Heart Association and American Stroke Association",
"    <span class=\"nowrap\">",
"     (AHA/ASA)",
"    </span>",
"    issued in 2011 recommend that patients with ischemic stroke or transient ischemic attack (TIA) who are heavy drinkers should eliminate or reduce their alcohol consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=see_link\">",
"     \"Brief intervention for unhealthy alcohol and other drug use\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Apolipoprotein E",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of apolipoprotein E (APOE) phenotypes in cerebrovascular disease and ischemic stroke is unsettled. This apolipoprotein is a ligand for hepatic chylomicron and VLDL remnant receptors, leading to clearance of these lipoproteins from the circulation, and for LDL receptors. The APOE e4 allele has been reported to be a stroke risk factor in some [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/67,68\">",
"     67,68",
"    </a>",
"    ] but not other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/69-73\">",
"     69-73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=see_link&amp;anchor=H8#H8\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\", section on 'Apolipoproteins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Hyperhomocysteinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased serum homocysteine concentrations are associated with an increased risk of coronary and cerebrovascular disease. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevated homocysteine appears to be associated with an increased risk of the large artery subtype of ischemic stroke, and possibly to the small artery subtype; it does not appear to be associated with cardioembolic or other stroke subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Unfortunately, there is evidence from several clinical trials that treatment with homocysteine-reducing vitamins is",
"    <strong>",
"     not",
"    </strong>",
"    beneficial for secondary prevention of cardiovascular disease or stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with ischemic stroke or TIA and hyperhomocysteinemia, the",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines of 2011 state that folate supplementation reduces levels of homocysteine and may be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/19\">",
"     19",
"    </a>",
"    ]. However, there is no evidence that reducing homocysteine levels prevents stroke recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of homocysteine\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Inflammatory markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mounting data suggest that inflammation plays a role in atherosclerosis and contributes to stroke risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     C-reactive protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;C-reactive protein (CRP) concentration is associated with the long-term risk of cardiovascular events, including ischemic stroke, as confirmed by a meta-analysis of 54 prospective studies and individual records from over 160,000 subjects without a history of vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=see_link\">",
"     \"C-reactive protein in cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34665?source=see_link\">",
"     \"Screening for cardiovascular risk with C-reactive protein\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While elevated CRP levels could be used as an additional marker of increased stroke risk, there are no randomized clinical trial data to support the hypothesis that lowering CRP levels will lead to reduced stroke risk. Furthermore, appropriate critical thresholds of CRP elevation and optimal timing of CRP measurements in the setting of acute cerebral ischemia have not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/77\">",
"     77",
"    </a>",
"    ]. Therefore, we do not recommend routinely checking CRP levels for primary or secondary ischemic stroke prevention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Fibrinogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma fibrinogen is associated with the risk of stroke and cardiovascular disease and may act by several possible mechanisms, including promotion of atherogenesis and inflammation, elevation of blood and plasma viscosity, increased platelet aggregability, and increased tendency to form fibrin within thrombus.",
"   </p>",
"   <p>",
"    Elevated fibrinogen levels appear to correlate with vulnerable atherosclerotic plaque characteristics, including thinning of the fibrous cap of atheroma predisposing to rupture, and to increased plaque inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/78\">",
"     78",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9608?source=see_link\">",
"     \"Pathophysiology of symptoms from carotid atherosclerosis\"",
"    </a>",
"    ). However, it is not established that elevated fibrinogen is an independent risk factor for carotid atherosclerosis progression, as some evidence suggests it is rather a nonspecific marker of inflammatory activity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The routine use of fibrinogen as a cardiovascular risk marker is limited by measurement variability. If fibrinogen is used clinically, three measurements should be obtained at each venipuncture, and a minimum of two sets of fibrinogen measurements are needed. Given the lack of clinical trial data, we do not generally recommend drug therapy specifically aimed at lowering the fibrinogen concentrations for patients at risk of ischemic stroke or progressive carotid disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Leukocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocyte counts and neutrophil counts were associated with ischemic events including stroke, myocardial infarction, and vascular death in a high-risk population [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/80\">",
"     80",
"    </a>",
"    ]. In the week before the recurrent event, the leukocyte count was significantly increased over baseline levels. However, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    did not modify the predictive effects of elevated leukocyte counts.",
"   </p>",
"   <p>",
"    An independent association of leukocyte count elevation with increased ischemic stroke risk was also found among stroke-free participants in a prospective, longitudinal, cohort study (the Northern Manhattan Study) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head and neck radiotherapy for cancer treatment may lead to a delayed vasculopathy of large and small vessels mediated by endothelial damage, fibrosis, and accelerated atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. Radiotherapy-related occlusive disease is often diffuse and occurs in uncommon locations, in contrast to the typical focal lesions that develop at vessel bifurcations from atherosclerosis in the absence of radiation.",
"   </p>",
"   <p>",
"    Depending on the site and dose of radiation, the involved vessels may include the extracranial carotid and vertebral arteries and the intracranial circle of Willis vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/82,85\">",
"     82,85",
"    </a>",
"    ]. This process may lead to symptomatic carotid disease, moyamoya syndrome, and ischemic stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3786?source=see_link&amp;anchor=H3#H3\">",
"     \"Moyamoya disease: Etiology, clinical features, and diagnosis\", section on 'Associated conditions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link&amp;anchor=H3822529#H3822529\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Carotid artery injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Vitamin and fish oil therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplementation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    , vitamin E, and vitamin C, either alone or in combination with each other or other antioxidant vitamins does not appear to be effective in the primary or secondary prevention of cardiovascular disease. The data supporting these conclusions are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=see_link\">",
"     \"Nutritional antioxidants in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fish oil (omega-3 fatty acids) consumption lowers serum triglyceride concentrations and appears to decrease the proportions of small dense LDL particles while increasing HDL-C levels. The evidence regarding fish oil intake and ischemic stroke risk is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=see_link&amp;anchor=H21#H21\">",
"     \"Fish oil and marine omega-3 fatty acids\", section on 'Stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     DISEASE MANAGEMENT PROGRAMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comprehensive disease management programs initiated during acute hospitalization may result in higher compliance and utilization rates of long-term preventive therapies and thereby improve patient outcomes. Examples include CHAMP [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/86\">",
"     86",
"    </a>",
"    ], ICARUSS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/87\">",
"     87",
"    </a>",
"    ], and PROTECT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/88-90\">",
"     88-90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The PROTECT program was designed to integrate proven secondary stroke prevention measures into the standard stroke care provided during acute hospital stay, with initiation and maintenance of the following goals for all patients with ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/88\">",
"     88",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antithrombotic therapy",
"     </li>",
"     <li>",
"      Statin therapy",
"     </li>",
"     <li>",
"      Angiotensin converting enzyme inhibitor or angiotensin receptor blocker therapy",
"     </li>",
"     <li>",
"      Thiazide diuretic therapy",
"     </li>",
"     <li>",
"      Smoking cessation advice and referral to a formal cessation program",
"     </li>",
"     <li>",
"      American Heart Association diet",
"     </li>",
"     <li>",
"      Exercise counseling",
"     </li>",
"     <li>",
"      Stroke education, including knowledge of stroke warning signs",
"     </li>",
"     <li>",
"      Awareness of need to call 911 in case of cerebrovascular event",
"     </li>",
"     <li>",
"      Awareness of individual's risk factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Implementation of this program was associated with a substantial increase in treatment utilization at the time of hospital discharge compared with conventional care [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/88\">",
"     88",
"    </a>",
"    ]. High rates of adherence were maintained at 90 days after discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       \"Patient information: Stroke (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/37/36435?source=see_link\">",
"       \"Patient information: Medicines after an ischemic stroke (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/40/39554?source=see_link\">",
"       \"Patient information: Lowering the risk of having another stroke (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"       \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association",
"    <span class=\"nowrap\">",
"     (AHA/ASA)",
"    </span>",
"    has published guidelines for the prevention of stroke in patients with ischemic stroke risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/19,91\">",
"     19,91",
"    </a>",
"    ]. All patients with atherosclerotic cerebrovascular disease should have risk factors controlled.",
"   </p>",
"   <p>",
"    Accumulating evidence suggests that blood pressure reduction and statin therapy lowers the risk of cardiovascular events in patients with stroke or at high risk for stroke, independent of the presence of specific risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/92\">",
"     92",
"    </a>",
"    ]. Current guidelines from the",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    incorporate this concept [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, most patients with an ischemic stroke or transient ischemic attack (TIA) should be treated with all available risk reduction strategies. Currently viable strategies include blood pressure reduction, statins, and antiplatelet therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Blood pressure reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2011 American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association guidelines recommend blood pressure reduction for the prevention of recurrent stroke and other vascular events in patients with an ischemic stroke and TIA who are beyond the hyperacute period [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/19\">",
"     19",
"    </a>",
"    ]. The treatment of blood pressure to reduce the risk of ischemic stroke is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17305?source=see_link\">",
"     \"Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommendations regarding blood pressure therapy for patients with other types of cardiovascular disease who are at risk for ischemic stroke and TIA are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Glucose control",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with diabetes who have had an ischemic stroke or TIA, we suggest glucose control to near normoglycemic levels. This recommendation is based on evidence that tight glucose control reduces microvascular complications. However, there is no evidence that intensive glucose-lowering therapy for patients with longstanding type 2 diabetes reduces the risk of macrovascular outcomes such as cardiovascular events, stroke, and death. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Glycemic control'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link&amp;anchor=H9#H9\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Macrovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diet, exercise, oral hypoglycemic drugs, and insulin are proven methods to achieve glycemic control. A reasonable goal of therapy is an A1C value of &le;7 percent for most patients. The treatment of blood glucose is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Cholesterol and statin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statin therapy reduces the risk of major vascular events including first-ever stroke, nonfatal myocardial infarction or coronary death, or any revascularization procedure. In addition, statin treatment appears to reduce the risk of recurrent ischemic stroke. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Statin therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with TIA or ischemic stroke of atherosclerotic origin who do not have known coronary heart disease, we recommend intensive lipid-lowering therapy with a statin to reduce the risk of stroke and cardiovascular events. We suggest treating with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    since this was the agent and dose used in the SPARCL trial that showed a benefit for secondary ischemic stroke prevention. Furthermore, we suggest a target LDL-C reduction of at &ge;50 percent or a target LDL-C level of &lt;70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&lt;1.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    to obtain maximum benefit. However, other factors (eg, liver or renal disease, concomitant medications) may influence the choice and dose of statin. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'SPARCL trial'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with TIA or ischemic stroke who also have a history of coronary heart disease (CHD) or a CHD equivalent (",
"    <a class=\"graphic graphic_table graphicRef71255 \" href=\"UTD.htm?43/30/44523\">",
"     table 1",
"    </a>",
"    ), the use of statin therapy and lipid modification is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link&amp;anchor=H9#H9\">",
"     \"Secondary prevention of cardiovascular disease\", section on 'Lipid modification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with ischemic stroke or TIA and an LDL-C level above goal (&lt;70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [&lt;1.8",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    who are intolerant of statin medications, we suggest treatment with another lipid lowering agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link\">",
"     \"Lipid lowering with drugs other than statins and fibrates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7800?source=see_link\">",
"     \"Lipid lowering with fibric acid derivatives\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with lifestyle-related risk factors including obesity, physical inactivity, elevated triglycerides, low HDL, or metabolic syndrome, we suggest therapeutic lifestyle modifications including reduction of dietary saturated fat and cholesterol intake. Other aspects of therapeutic lifestyle modification, such as weight reduction and increased physical activity, are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Lifestyle modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of behavioral and lifestyle modifications may be beneficial for reducing the risk of ischemic stroke and cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/93\">",
"     93",
"    </a>",
"    ]. Smoking cessation, limited alcohol consumption, weight control, regular aerobic physical activity, salt restriction, and a diet that is rich in fruits, vegetables, and low-fat dairy products are recommended by the 2011",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?29/61/30682/abstract/19\">",
"     19",
"    </a>",
"    ]. Our recommendations are in concordance with the national guidelines.",
"   </p>",
"   <p>",
"    For patients with ischemic stroke or TIA who are recent or current tobacco smokers, we recommend smoking cessation. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Smoking'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with ischemic stroke or TIA who are heavy drinkers, we recommend elimination or reduction of alcohol consumption because of the increased risk of stroke and high morbidity associated with alcoholism, despite the lack of clear evidence from clinical trials that reduction of alcohol intake decreases the risk of recurrent stroke. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Alcohol intake'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=see_link&amp;anchor=H11#H11\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\", section on 'Stroke risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with ischemic stroke or TIA who are capable of regular exercise, we suggest moderate intensity physical exercise most days of the week for at least 30 minutes. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Metabolic syndrome'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the benefits and risks of exercise\", section on 'Benefits of exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all patients with TIA or ischemic stroke of atherosclerotic origin should also receive an antiplatelet agent. The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"     aspirin-extended-release dipyridamole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    alone, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    alone are all acceptable options for initial therapy.",
"   </p>",
"   <p>",
"    We suggest initial therapy with the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"     aspirin-extended-release dipyridamole",
"    </a>",
"    25",
"    <span class=\"nowrap\">",
"     mg/200",
"    </span>",
"    mg twice a day, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    for patients with noncardioembolic ischemic stroke or TIA of atherothrombotic, lacunar, or cryptogenic type, as long as this choice will not impose a substantial financial burden. Initial therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is appropriate for patients who cannot afford, cannot obtain, or cannot tolerate the more effective antiplatelet agents (aspirin-extended-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , or clopidogrel).",
"   </p>",
"   <p>",
"    The use of antiplatelet therapy for secondary stroke prevention is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11363442\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors of UpToDate would like to acknowledge Dr. Janet Wilterdink and Dr. Philip Kistler, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/1\">",
"      Bogousslavsky J, Regli F, Van Melle G. Risk factors and concomitants of internal carotid artery occlusion or stenosis. A controlled study of 159 cases. Arch Neurol 1985; 42:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/2\">",
"      Candelise L, Bianchi F, Galligoni F, et al. Italian multicenter study on reversible cerebral ischemic attacks: III--Influence of age and risk factors on cerebrovascular atherosclerosis. Stroke 1984; 15:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/3\">",
"      Crouse JR, Toole JF, McKinney WM, et al. Risk factors for extracranial carotid artery atherosclerosis. Stroke 1987; 18:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/4\">",
"      Harmsen P, Lappas G, Rosengren A, Wilhelmsen L. Long-term risk factors for stroke: twenty-eight years of follow-up of 7457 middle-aged men in G&ouml;teborg, Sweden. Stroke 2006; 37:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/5\">",
"      Hankey GJ. Potential new risk factors for ischemic stroke: what is their potential? Stroke 2006; 37:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/6\">",
"      Mannami T, Baba S, Ogata J. Strong and significant relationships between aggregation of major coronary risk factors and the acceleration of carotid atherosclerosis in the general population of a Japanese city: the Suita Study. Arch Intern Med 2000; 160:2297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/7\">",
"      Liao D, Myers R, Hunt S, et al. Familial history of stroke and stroke risk. The Family Heart Study. Stroke 1997; 28:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/8\">",
"      Brass LM, Isaacsohn JL, Merikangas KR, Robinette CD. A study of twins and stroke. Stroke 1992; 23:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/9\">",
"      Rubattu S, Ridker P, Stampfer MJ, et al. The gene encoding atrial natriuretic peptide and the risk of human stroke. Circulation 1999; 100:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/10\">",
"      Gorelick PB, Caplan LR, Hier DB, et al. Racial differences in the distribution of anterior circulation occlusive disease. Neurology 1984; 34:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/11\">",
"      Sacco RL. Clinical practice. Extracranial carotid stenosis. N Engl J Med 2001; 345:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/12\">",
"      Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/13\">",
"      MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/14\">",
"      Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol 2007; 6:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/15\">",
"      Prabhakaran S, Wright CB, Yoshita M, et al. Prevalence and determinants of subclinical brain infarction: the Northern Manhattan Study. Neurology 2008; 70:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/16\">",
"      Das RR, Seshadri S, Beiser AS, et al. Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study. Stroke 2008; 39:2929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/17\">",
"      Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/18\">",
"      Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 2010; 375:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/19\">",
"      Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/20\">",
"      Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation 1997; 96:3243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/21\">",
"      Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation and decreased risk of stroke in women. JAMA 1993; 269:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/22\">",
"      Kurth T, Kase CS, Berger K, et al. Smoking and risk of hemorrhagic stroke in women. Stroke 2003; 34:2792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/23\">",
"      Wilson PW, Hoeg JM, D'Agostino RB, et al. Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. N Engl J Med 1997; 337:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/24\">",
"      Li C, Engstr&ouml;m G, Hedblad B, et al. Risk factors for stroke in subjects with normal blood pressure: a prospective cohort study. Stroke 2005; 36:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/25\">",
"      Wolf PA, D'Agostino RB, Kannel WB, et al. Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA 1988; 259:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/26\">",
"      Wannamethee SG, Shaper AG, Whincup PH, Walker M. Smoking cessation and the risk of stroke in middle-aged men. JAMA 1995; 274:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/27\">",
"      Arvanitakis Z, Schneider JA, Wilson RS, et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 2006; 67:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/28\">",
"      Janghorbani M, Hu FB, Willett WC, et al. Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: the Nurses' Health Study. Diabetes Care 2007; 30:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/29\">",
"      Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/30\">",
"      Luitse MJ, Biessels GJ, Rutten GE, Kappelle LJ. Diabetes, hyperglycaemia, and acute ischaemic stroke. Lancet Neurol 2012; 11:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/31\">",
"      Vermeer SE, Sandee W, Algra A, et al. Impaired glucose tolerance increases stroke risk in nondiabetic patients with transient ischemic attack or minor ischemic stroke. Stroke 2006; 37:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/32\">",
"      Vitelli LL, Shahar E, Heiss G, et al. Glycosylated hemoglobin level and carotid intimal-medial thickening in nondiabetic individuals. The Atherosclerosis Risk in Communities Study. Diabetes Care 1997; 20:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/33\">",
"      J&oslash;rgensen L, Jenssen T, Joakimsen O, et al. Glycated hemoglobin level is strongly related to the prevalence of carotid artery plaques with high echogenicity in nondiabetic individuals: the Troms&oslash; study. Circulation 2004; 110:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/34\">",
"      Koren-Morag N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke 2005; 36:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/35\">",
"      Kurl S, Laukkanen JA, Niskanen L, et al. Metabolic syndrome and the risk of stroke in middle-aged men. Stroke 2006; 37:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/36\">",
"      Chen HJ, Bai CH, Yeh WT, et al. Influence of metabolic syndrome and general obesity on the risk of ischemic stroke. Stroke 2006; 37:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/37\">",
"      Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005; 165:2644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/38\">",
"      Ninomiya T, Kubo M, Doi Y, et al. Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population: the Hisayama study. Stroke 2007; 38:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/39\">",
"      Boden-Albala B, Sacco RL, Lee HS, et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke 2008; 39:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/40\">",
"      Wang J, Ruotsalainen S, Moilanen L, et al. The metabolic syndrome predicts incident stroke: a 14-year follow-up study in elderly people in Finland. Stroke 2008; 39:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/41\">",
"      Rodriguez-Colon SM, Mo J, Duan Y, et al. Metabolic syndrome clusters and the risk of incident stroke: the atherosclerosis risk in communities (ARIC) study. Stroke 2009; 40:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/42\">",
"      Piechowski-J&oacute;wiak B, Bogousslavsky J. Cholesterol as a risk factor for stroke: the fugitive? Stroke 2004; 35:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/43\">",
"      Thrift AG. Cholesterol is associated with stroke, but is not a risk factor. Stroke 2004; 35:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/44\">",
"      Donnan GA, Davis SM. Stroke and cholesterol: weakness of risk versus strength of therapy. Stroke 2004; 35:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/45\">",
"      Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 1995; 346:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/46\">",
"      Iso H, Jacobs DR Jr, Wentworth D, et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989; 320:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/47\">",
"      Lindenstr&oslash;m E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ 1994; 309:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/48\">",
"      Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Lancet 1998; 352:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/49\">",
"      Tirschwell DL, Smith NL, Heckbert SR, et al. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 2004; 63:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/50\">",
"      Corvol JC, Bouzamondo A, Sirol M, et al. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Intern Med 2003; 163:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/51\">",
"      Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008; 300:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/52\">",
"      H&aring;heim LL, Holme I, Hjermann I, Leren P. Risk factors of stroke incidence and mortality. A 12-year follow-up of the Oslo Study. Stroke 1993; 24:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/53\">",
"      Shahar E, Chambless LE, Rosamond WD, et al. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2003; 34:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/54\">",
"      Amarenco P. Lipid lowering and recurrent stroke: another stroke paradox? Eur Heart J 2005; 26:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/55\">",
"      Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med 1998; 128:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/56\">",
"      Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/57\">",
"      Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/58\">",
"      Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/59\">",
"      Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/60\">",
"      Coull BM. Statin therapy after acute ischemic stroke in the heart protection study: is the role in recurrent stroke prevention now defined? Stroke 2004; 35:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/61\">",
"      Amarenco P, Labreuche J, Lavall&eacute;e P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004; 35:2902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/62\">",
"      Plehn JF, Davis BR, Sacks FM, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 1999; 99:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/63\">",
"      Sever PS, Dahl&ouml;f B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/64\">",
"      Hegland O, Dickstein K, Larsen JP. Effect of simvastatin in preventing progression of carotid artery stenosis. Am J Cardiol 2001; 87:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/65\">",
"      de Sauvage Nolting PR, de Groot E, Zwinderman AH, et al. Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin. Arch Intern Med 2003; 163:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/66\">",
"      De Schryver EL, Algra A, Kappelle LJ, et al. Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin. Cochrane Database Syst Rev 2012; 9:CD001342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/67\">",
"      McCarron MO, Delong D, Alberts MJ. APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis. Neurology 1999; 53:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/68\">",
"      Schneider JA, Bienias JL, Wilson RS, et al. The apolipoprotein E epsilon4 allele increases the odds of chronic cerebral infarction [corrected] detected at autopsy in older persons. Stroke 2005; 36:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/69\">",
"      Basun H, Corder EH, Guo Z, et al. Apolipoprotein E polymorphism and stroke in a population sample aged 75 years or more. Stroke 1996; 27:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/70\">",
"      Zhu L, Fratiglioni L, Guo Z, et al. Incidence of dementia in relation to stroke and the apolipoprotein E epsilon4 allele in the very old. Findings from a population-based longitudinal study. Stroke 2000; 31:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/71\">",
"      Frikke-Schmidt R, Nordestgaard BG, Thudium D, et al. APOE genotype predicts AD and other dementia but not ischemic cerebrovascular disease. Neurology 2001; 56:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/72\">",
"      Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol 2004; 61:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/73\">",
"      Sturgeon JD, Folsom AR, Bray MS, et al. Apolipoprotein E genotype and incident ischemic stroke: the Atherosclerosis Risk in Communities Study. Stroke 2005; 36:2484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/74\">",
"      Eikelboom JW, Hankey GJ, Anand SS, et al. Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke 2000; 31:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/75\">",
"      Iso H, Moriyama Y, Sato S, et al. Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation 2004; 109:2766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/76\">",
"      Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/77\">",
"      Di Napoli M, Schwaninger M, Cappelli R, et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 2005; 36:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/78\">",
"      Mauriello A, Sangiorgi G, Palmieri G, et al. Hyperfibrinogenemia is associated with specific histocytological composition and complications of atherosclerotic carotid plaques in patients affected by transient ischemic attacks. Circulation 2000; 101:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/79\">",
"      Sabeti S, Exner M, Mlekusch W, et al. Prognostic impact of fibrinogen in carotid atherosclerosis: nonspecific indicator of inflammation or independent predictor of disease progression? Stroke 2005; 36:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/80\">",
"      Grau AJ, Boddy AW, Dukovic DA, et al. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke 2004; 35:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/81\">",
"      Elkind MS, Sciacca RR, Boden-Albala B, et al. Relative elevation in baseline leukocyte count predicts first cerebral infarction. Neurology 2005; 64:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/82\">",
"      Morris B, Partap S, Yeom K, et al. Cerebrovascular disease in childhood cancer survivors: A Children's Oncology Group Report. Neurology 2009; 73:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/83\">",
"      Lam WW, Leung SF, So NM, et al. Incidence of carotid stenosis in nasopharyngeal carcinoma patients after radiotherapy. Cancer 2001; 92:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/84\">",
"      Plummer C, Henderson RD, O'Sullivan JD, Read SJ. Ischemic stroke and transient ischemic attack after head and neck radiotherapy: a review. Stroke 2011; 42:2410.",
"     </a>",
"    </li>",
"    <li>",
"     Kasner, SE. Treatment of \"other\" causes of stroke. In Stroke: pathophsyiology, diagnosis, and management, eds Mohr, JP, Choi, DW, Grotta, JC, et al, 4th ed. Churchill Livingstone, Philadelphia, 2004, p. 1059.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/86\">",
"      Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001; 87:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/87\">",
"      Joubert J, Reid C, Barton D, et al. Integrated care improves risk-factor modification after stroke: initial results of the Integrated Care for the Reduction of Secondary Stroke model. J Neurol Neurosurg Psychiatry 2009; 80:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/88\">",
"      Ovbiagele B, Saver JL, Fredieu A, et al. PROTECT: a coordinated stroke treatment program to prevent recurrent thromboembolic events. Neurology 2004; 63:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/89\">",
"      Ovbiagele B, Saver JL, Fredieu A, et al. In-hospital initiation of secondary stroke prevention therapies yields high rates of adherence at follow-up. Stroke 2004; 35:2879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/90\">",
"      Ovbiagele B. Pathways to further boost treatment rates and clinical outcomes in hospitalized stroke patients. Crit Pathw Cardiol 2010; 9:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/91\">",
"      Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/92\">",
"      Elkind MS. Implications of stroke prevention trials: treatment of global risk. Neurology 2005; 65:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/61/30682/abstract/93\">",
"      Zhang Y, Tuomilehto J, Jousilahti P, et al. Lifestyle factors on the risks of ischemic and hemorrhagic stroke. Arch Intern Med 2011; 171:1811.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1120 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-B63444C5D6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_61_30682=[""].join("\n");
var outline_f29_61_30682=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTOR IMPACT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SMOKING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIABETES MELLITUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Glycemic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Metabolic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DYSLIPIDEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ischemic and hemorrhagic stroke risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Statin therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - SPARCL trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - HPS trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Utility despite normal cholesterol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Potential mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ANTITHROMBOTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OTHER FACTORS INFLUENCING RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Alcohol intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Apolipoprotein E",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Hyperhomocysteinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Inflammatory markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Fibrinogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Leukocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Vitamin and fish oil therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      DISEASE MANAGEMENT PROGRAMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Blood pressure reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Glucose control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Cholesterol and statin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Lifestyle modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11363442\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1120\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1120|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/18/12591\" title=\"figure 1A\">",
"      Stroke mortality related to BP and age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/61/20447\" title=\"figure 1B\">",
"      CHD mortality related to BP and age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1120|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/30/44523\" title=\"table 1\">",
"      CHD risk equivalents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?10/25/10642?source=related_link\" title=\"calculator 1\">",
"      Calculator: Stroke Risk in Female Patients 55-84 Years Old (Framingham data)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/43/9906?source=related_link\" title=\"calculator 2\">",
"      Calculator: Stroke Risk in Male Patients 55-84 Years Old (Framingham data)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17305?source=related_link\">",
"      Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=related_link\">",
"      Brief intervention for unhealthy alcohol and other drug use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=related_link\">",
"      Fish oil and marine omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7800?source=related_link\">",
"      Lipid lowering with fibric acid derivatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3786?source=related_link\">",
"      Moyamoya disease: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=related_link\">",
"      Nutritional antioxidants in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=related_link\">",
"      Overview of the benefits and risks of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9608?source=related_link\">",
"      Pathophysiology of symptoms from carotid atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/40/39554?source=related_link\">",
"      Patient information: Lowering the risk of having another stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/37/36435?source=related_link\">",
"      Patient information: Medicines after an ischemic stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=related_link\">",
"      Patterns of tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=related_link\">",
"      Pharmacotherapy for alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=related_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34665?source=related_link\">",
"      Screening for cardiovascular risk with C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32281?source=related_link\">",
"      Secondary prevention for specific causes of ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_61_30683="Adherence improvement HCW";
var content_f29_61_30683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Strategies to improve adherence: clinician and health team-related",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Establish trust.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serve as educator and information source with ongoing support and",
"monitoring.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide access between visits for questions or problems (eg, by",
"providing a pager number), including during vacations or conferences.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitor ongoing adherence; intensify management during periods of",
"suboptimal adherence (ie, more frequent visits, recruitment of family",
"or friends,",
"deployment of other team members, and referral for mental health or",
"chemical-dependency services).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use health team for all patients, including patients with special needs",
"(eg, use peer educators for adolescents or for injection-drug users).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider impact of new diagnoses on adherence (eg, depression, liver",
"disease, wasting, or recurrent chemical dependency) and include",
"adherence intervention in management.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use nurses, pharmacists, peer educators, volunteers, case managers,",
"drug counselors, clinician's assistants, nurse practitioners, and",
"research nurses to reinforce adherence messages.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide training to support team regarding antiretroviral therapy and",
"adherence.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Add adherence interventions to job descriptions of support team",
"members; add continuity-of-care role to improve patient access.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     file://aidsinfo.nih.gov.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_61_30683=[""].join("\n");
var outline_f29_61_30683=null;
var title_f29_61_30684="ML treatment";
var content_f29_61_30684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F88694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F88694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug regimens for treatment of mucosal leishmaniasis in adults",
"    <sup>",
"     [1-3]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"60%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Pentavalent antimonials*",
"       </td>",
"       <td>",
"        Sodium stibogluconate",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        20 mg/kg intravenously or intramuscularly per day for 28 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meglumine antimoniate",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        20 mg/kg intravenously or intramuscularly per day for 30 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Amphotericin",
"       </td>",
"       <td>",
"        Amphotericin B deoxycholate",
"       </td>",
"       <td>",
"        1 mg/kg intravenously per day or every other day, up to total cumulative dose of 2.5 to 3 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liposomal amphotericin B (AmBisome)",
"       </td>",
"       <td>",
"        3 to 5 mg/kg intravenously once daily (no more than 200 mg daily) up to total cumulative dose of 40 mg/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Miltefosine",
"       </td>",
"       <td>",
"        Miltefosine",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        2.5 mg/kg orally (maximum 150 mg) once daily for 28 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pentamidine",
"       </td>",
"       <td>",
"        Pentamidine isethionate",
"       </td>",
"       <td>",
"        4 mg/kg intravenously or intramuscularly per day or every other day, until healed or up to total dose of 2 g",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Agents listed, dosage regimens, and combinations are effective only against certain Leishmania species/strains and only in certain areas of the world. The therapeutic approach to mucosal leishmaniasis is discussed in the topic 'Treatment of cutaneous leishmaniasis.' Pediatric dosing is summarized separately",
"    <sup>",
"     [3]",
"    </sup>",
"    .",
"    <div class=\"footnotes\">",
"     * Pentavalent antimonials may be administered with pentoxifylline (400 mg orally three times a day) for synergistic activity.",
"     <br/>",
"     &Delta; In the United States, may be obtained from CDC Drug Services telephone 404-639-3670 or 404-639-2888 (nights, weekends).",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Not commercially available in US. It may be possible to obtain via investigational new drug application to FDA.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of authors with additional data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Goto H and Laulett Lindoso JA; Cutaneous and mucocutaneous leishmaniasis; Inf Dis Clin N Am 2012; 26:293.",
"      </li>",
"      <li>",
"       Parasites - Leishmaniasis; Centers for Disease Control and Prevention",
"       <a href=\"file://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html#tx\" target=\"_blank\">",
"        file://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html#tx",
"       </a>",
"       (accessed March 25, 2013).",
"      </li>",
"      <li>",
"       Drugs for parasitic infections 2nd ed; The Medical Letter 2010; New Rochelle N.Y. p.26.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_61_30684=[""].join("\n");
var outline_f29_61_30684=null;
var title_f29_61_30685="Paraneoplastic syndromes associated with lung cancer";
var content_f29_61_30685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Paraneoplastic syndromes associated with lung cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Systemic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Anorexia, cachexia, weight loss*",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fever",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Orthostatic hypotension",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Nonbacterial thrombotic endocarditis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Dermatomyositis/polymyositis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Systemic lupus erythematosus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Cutaneous",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Acquired hypertrichosis lanuginosa",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Acrokeratosis (Bazex's syndrome)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Clubbing*",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Dermatomyositis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Erythema gyratum repens",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Exfoliative dermatitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hypertrophic pulmonary osteoarthropathy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Deep venous thrombosis (Trousseau's syndrome)*",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tripe palms",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Acanthosis nigricans",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Acquired ichthyosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Acquired palmoplantar keratoderma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Erythema annulare centrifugum",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Florid cutaneous papillomatosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pemphigus vulgaris",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pityriasis rotunda",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pruritus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sign of Leser-Trelat",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sweet's syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Vasculitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Renal",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Glomerulopathies",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tubulointerstitial disorders",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Endocrine/metabolic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cushing's syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hypercalcemia*",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hyponatremia*",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hyperglycemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hypertension",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Acromegaly",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hyperthyroidism",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hypercalcitoninemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Gynecomastia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Galactorrhea",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Carcinoid syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hypoglycemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hypophosphatemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Lactic acidosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hypouricemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hyperamylasemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Hematologic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Anemia*",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Polycythemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hypercoagulability",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Thrombocytopenic purpura",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Dysproteinemia (including amyloidosis)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Leukocytosis/Leukoerythroblastic reaction",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Eosinophilia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Neurologic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Peripheral neuropathy*",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Lambert-Eaton myasthenic syndrome*",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Necrotizing myelopathy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cerebral encephalopathy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Visual loss",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Visceral neuropathy",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Indicates more common paraneoplastic syndromes.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Patel AM, Jett JR, Clinical presentation and staging of lung cancer. In: Comprehensive Textbook of Thoracic Oncology, Aisner J, Arrigada R, Green MR, et al (Eds), Williams &amp; Wilkins, Baltimore, 1996, p. 293.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_61_30685=[""].join("\n");
var outline_f29_61_30685=null;
var title_f29_61_30686="CLL nomogram for time to first treatment";
var content_f29_61_30686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 621px\">",
"   <div class=\"ttl\">",
"    Nomogram for time to first treatment in patients with chronic lymphocytic leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 601px; height: 446px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nomogram used by totaling points identified at top scale for each of four independent variables. Point score for LDH identified based on IGHV mutation status. This summed point score then identified on total point scale to identify two- and four-year treatment-free probability and estimate treatment-free survival. FISH was categorized by Dohner hierarchic categorization.",
"    <div class=\"footnotes\">",
"     LN: lymph node; LDH: lactate dehydrogenase; IGHV: immunoglobulin heavy chain variable gene; FISH: fluorescent in situ hybridization; prob: probability.",
"    </div>",
"    <div class=\"reference\">",
"     From: Wierda WG, O'Brien S, Wang X, et al. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol 2011; 29:4088. Reprinted with permission. Copyright &copy; 2011 American Society of Clinical Oncology. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_61_30686=[""].join("\n");
var outline_f29_61_30686=null;
var title_f29_61_30687="Aphthous ulcer";
var content_f29_61_30687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aphthous ulcer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 200px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martha Ann Keels, DDS, PhD, Duke Pediatric Dentistry.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_61_30687=[""].join("\n");
var outline_f29_61_30687=null;
